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ABSTRACT 
 Systemic sclerosis (SSc; scleroderma) is a chronic multisystem autoimmune 
disease that includes prominent skin involvement in all patients and is characterized by 
fibrosis, inflammation, and microvascular injury of the skin and internal organs.  Clinical 
trial design for patients with systemic sclerosis (SSc) has been confounded by the 
heterogeneity of disease progression and lack of objective outcome measures. This has 
hampered identification of therapies for patients who have frequently fatal fibrotic 
complications. Direct pulmonary complications are the leading cause of death in SSc. For 
clinical trials in patients with diffuse cutaneous SSc, identification of a pharmacodynamic 
biomarker associated with clinical improvement would allow for alternative approaches 
to trial design. Furthermore, identification of a diagnostic biomarker for SSc complicated 
by pulmonary arterial hypertension (SSc-PAH) would provide a reliable non-invasive 
method for diagnosis of pulmonary arterial hypertension.  
Through the combination of high throughput technologies and clinical 
information we have identified three preliminary biomarkers for SSc:  i) Two 
pharmacodynamic biomarkers for diffuse skin disease (dcSSc), one in using mRNA from 
skin biopsies and one using proteomic profiles from sera;  ii) a serum based proteomic 
classifier for the screening and diagnostic evaluation of pulmonary arterial hypertension 
		 vii 
in systemic sclerosis.  
We show these biomarkers can be applied to assess changes in skin disease in 
dSSc patients over time and with further development could be used to supplement or 
replace the physical examination assessment (Modified Rodnan Skin Score, MRSS) as an 
outcome measure in clinical trials for dcSSc patients. Routine use of these biomarkers in 
SSc clinical trial design could expand treatment options for a patient population that 
currently has few if any treatment options that slow progression of disease.  
Furthermore we identified a serum biomarker for the major SSc pulmonary 
complication, SSc-PAH. This diagnostic SSc-PAH biomarker has the potential to be used 
as a screening tool in order to reduce the need for unnecessary invasive diagnostic 
procedures. This non-invasive screening method could lead to early diagnosis thus 
improving patient survival and aid in clinical management of a complication for which 
there are several treatments but which is still frequently fatal.  
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CHAPTER ONE: INTRODUCTION 
Systemic Sclerosis 
Systemic sclerosis (SSc; scleroderma) is a chronic multisystem autoimmune disease that 
is characterized by fibrosis, inflammation, and microvascular injury of the skin and 
internal organs.  The prevalence of SSc in the United States adult population has been 
estimated to be 276 cases per million adults, with the disease affecting women five times 
more frequently than men(1). There are woefully inadequate treatment options and the 
median survival after diagnosis is about 11 years(2). Although SSc mainly manifests in 
middle-aged women (median age of 45 at time of diagnosis), it can also affect younger 
women, men, children, and the elderly and has one of the highest morality rates of the 
rheumatic diseases(3).  
SSc patients’ clinical manifestations are heterogeneous, which can make early and 
accurate diagnosis challenging. Patients are generally divided based on clinical 
presentation into two groups: limited cutaneous systemic sclerosis (lcSSc) and diffuse 
cutaneous systemic sclerosis (dcSSc) based on the extent of skin involvement. The more 
widespread involvement, including trunk and proximal extremities, is classified as diffuse 
while patients with limited disease have less extensive cutaneous fibrosis involvement of 
only the hands, feet, forearms and face (4).  
As a systemic disease there are several organs that can become involved in SSc. 
Historically the kidneys were particularly vulnerable and for many years scleroderma 
renal crisis (SRC) was the leading cause of death of SSc patients. This changed as 
aggressive use of angiotensin-converting-enzyme (ACE) inhibitors now helps prevent 
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renal failure in most of these patients. Direct lung involvement is now the most common 
cause of death in SSc patients, with interstitial lung disease (ILD) leading to pulmonary 
fibrosis (PF), and vascular obliteration leading to pulmonary arterial hypertension (PAH). 
The gastrointestinal tract can also be affected with smooth muscle atrophy and fibrosis, 
resulting in malabsorption and malnutrition, sometimes requiring hyperalimentation. SSc 
patients can also have cardiac involvement with ischemia-reperfusion and fibrosis leading 
to severe arrhythmia or congestive heart failure(5). 
Treatment for SSc is generally focused on management of critical organ 
complications(6). Current treatment for SSc fibrosis is limited to modestly beneficial 
effects of cyclophosphamide on lung function, quality of life and skin thickening(7). 
Immunoablation and autologous stem cell transplant is the only other proven option 
available to patients, with more dramatic potential benefits, but with associated risks of 
morbidity and mortality(8). Currently measurement of skin disease severity in SSc 
patients is assessed by a measurement of skin thickness as quantified by the modified 
Rodnan skin score (MRSS as measured from 0 to 51).  It has been shown that an increase 
in MRSS (MRSS≥20) correlates with internal organ complications and increased risk of 
mortality and a decrease in MRSS is correlated with improved survival(9, 10).  
Currently, change in skin score is the most commonly used primary outcome 
measure of a patient’s response to a treatment in a clinical trial. There are several 
problems associated with using skin score as an outcome measure. The clinical course of 
the disease is variable and due to disease atrophy some patients have spontaneous 
regression of their skin disease, which confounds the interpretation of trial results  
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Another problem with skin score again especially in early phase un-blinded trials 
is the physician performing the skin score may be influenced by their knowledge of the 
treatment. Additionally as the scoring is subjective and consequently there is variability 
between doctors performing the score.(11) In an effort to define more objective measures 
of disease people tend to use biomarkers  
 
Biomarkers in Systemic Sclerosis 
Biomarkers are objective measures indicative of a biological process. They could 
thus aid development of new therapeutics and clinical management of SSc patients. Our 
group has pioneered the discovery and use of biomarkers in SSc (12-18). Biomarkers that 
would be useful in SSc can be classified as diagnostic, prognostic, predictive, and 
pharmacodynamic (PD). A diagnostic biomarker is used as a tool for identification of 
patients who have a particular disease, condition, complication or subset in the multi-
system rheumatic diseases. Prognostic biomarkers indicate the future clinical course of 
the patient in the context of a particular clinical outcome without regard to treatment, 
while predictive biomarkers give information about the likelihood of a patient responding 
to a specific treatment. There are also pharmacodynamic biomarkers and these are used 
during the course of a clinical trial as response indicators to treatment.  
In the studies presented here the focused on pharmacodynamics biomarkers for 
the skin and diagnostic biomarkers for SSc associated pulmonary arterial hypertension 
(SSc-PAH).  Clinical trials using skin disease as the outcome in SSc patients have been 
largely focused on “early” dcSSc patients who generally experience more rapid and 
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severe thickening of their skin, associated with significant morbidity and mortality. 
“Early” dcSSc has typically been defined as being within two years after disease onset 
(first non-Raynaud’s symptom). The MRSS has historically been used as the primary 
outcome measure of response in SSc clinical trials. However, the MRSS can peak at 
different times in different patients and then sometimes stabilizes or regresses. Thus, 
interpretation of clinical trials, particularly early phase, open-label trials has been 
confounded by the use of MRSS since some patients would be expected to “improve” 
spontaneously. In addition, the physicians preforming the MRSS may be influenced by 
their knowledge of the treatment. Identification of a therapeutic response biomarker 
(pharmacodynamic biomarker) that could be utilized as supplement to another clinical 
outcome measure or in early phase clinical trials as a surrogate outcome measure would 
improve the objectivity of evaluation of patients, and eventually help in the clinical 
management in routine practice, and lead to faster identification of new treatment 
options.  
SSc patients with pulmonary disease have an estimated 52% 3-year survival rate, 
and the greatest number of deaths in both lcSSc and dcSSc patients(19). In the diffuse 
population the major lung complication is due to fibrosis and manifests as interstitial lung 
disease (ILD) and in the limited population the major lung complication is due to 
vascular damage, which manifests as pulmonary arterial hypertension (PAH). Early and 
accurate diagnosis of PAH is clinically challenging. SSc-PAH diagnosis currently relies 
on right heart catheterization (RHC), an invasive procedure that is typically only 
performed in patients with high suspicion of having PAH based on echocardiogram and 
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other weakly correlative criteria(20). Earlier diagnoses and faster treatment is associated 
with better outcomes for patients(21). Identification of a diagnostic biomarker that would 
allow for rapid non-invasive diagnoses could improve patient survival, and obviate or 
reduce the need for diagnostic right heart catheterizations.  
Skin Biomarkers in Systemic Sclerosis 
Due to the easy accessibility and universal involvement of the skin in patients 
with dcSSc, skin tissue has become are the most well studied site for markers of disease 
status. Additionally the skin is the only tissue that can be routinely biopsied and re-
biopsied. This makes mRNA levels in skin particularly valuable for monitoring response 
to therapy, and a particularly interesting site for potential pharmacodynamic biomarkers. 
This led us to speculate that skin mRNA levels could be used for assessing whether a 
drug is effectively engaging its intended targets, over the course of a clinical trial. 
Gene expression profiling permits a systematic approach to identification of 
pharmacodynamic biomarkers in SSc skin. Integration of clinical and biological 
outcomes also provides a much more powerful methodology for identifying pathogenic 
pathways than either in isolation. Previous work has shown that many genes show altered 
expression in SSc compared to healthy skin. In fact, subsets of SSc have been identified 
using differences in gene expression patterns in skin(22). However, many of these 
alterations in gene expression are unlikely to be central to disease pathogenesis. 
Although, mRNA from the skin shows many differences only a subset of these genes 
correlates with the clinical outcome measure of MRSS. Several years ago a 
pharmacodynamic biomarker of skin disease was described (12). This biomarker was 
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derived from differences from healthy controls and cross-sectional correlations with 
MRSS. It was composed of a combination of genes chosen based on biological relevance. 
Two of the genes that comprised the biomarker Thrombospondin-1: THBS1 and cartilage 
oligomeric protein 1: COMP, are known to be regulated by TGF-b and two other genes, 
Sialoadhesin: SIGLEC1 and Interferon-Induced Protein 44: IFI44, are known to be 
regulated by interferon. These genes were combined into a "four-gene biomarker" using 
multiple linear regression. Although, this biomarker correlated highly with the MRSS in a 
cross-sectional study it was limited in its utility since a pharmacodynamic biomarker 
really needs to be based on change. A pharmacodynamic biomarker requires movement 
of the biomarker over time corresponding with a clinical measure of disease severity and 
in the original study only five patients were examined longitudinally using the four-gene 
biomarker. Here we utilize a novel approach to study gene expression in SSc skin both 
cross-sectional as well as longitudinal, selecting genes on the basis of their relation to the 
MRSS. 
We used several mRNA datasets from SSc skin, including our large repository 
and several clinical trials. We used our repository from routine clinic visits as our 
discovery patient populations. These studies provide access to clinical trial data sets with 
associated skin biopsy mRNA collected longitudinally. In addition we used samples from 
SSc clinical trials including our clinical trial of the anti-TGFβ monoclonal antibody 
fresolimumab as well as nilotinib and tocilizumab from academic and industry 
collaborators, respectively, that to further validate skin mRNA PD biomarkers identified 
in our studies. These clinical trials were particularly interesting as biopsies were collected 
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both before and after treatment. In regard to our mRNA skin gene expression studies, we 
were able to take advantage of the efficiency of the nanostring platform to take our gene 
expression studies from discovery and validation to a clinically useful test. The 
nanostring instrument allows rapid and cost effective measurements of several hundred 
pre-selected mRNAs simultaneously (23).  
Serum Biomarkers in Systemic Sclerosis 
Although skin biomarkers have the virtue of assessing disease directly in the 
target organ, it would be much easier and less painful for patients if we could identify 
circulating serum biomarkers that measure skin disease activity. Many serum and plasma 
biomarkers have been identified as deregulated in dSSc skin disease. Much like the 
mRNA data in the skin, some of these proteins appear to be markers of fibrosis and/or are 
regulated by TGF-b.  One of the mRNA genes used in the four-gene biomarker described 
above, COMP, is also increased in sera from SSc patients and correlates moderately well 
with the MRSS (r=0.57) (12, 24). The other TGF-b-regulated protein included in the 
four-gene biomarker THBS1, is also increased in SSc sera(25). Concentrations of other 
TGF-b proteins, such as MMP-9, correlate relatively well with the MRSS (r= 0.425) (26).  
Several serum biomarkers relating to fibrosis for SSc were used in the negative CAT-192 
(anti-TGFβ1 antibody) trial. N propeptide of type I (PINP) was the only one associated 
with change in skin score during the trial(27). The CAT-192 trial did not include COMP, 
THBS1 or MMP-9 as outcome measures.  
Again mirroring the work published in the skin, a relationship between 
inflammation and fibrosis in disease pathogenesis is also strongly supported by the 
		
8 
upregulation of both profibrotic and pro-inflammatory biomarkers in the serum and 
plasma of SSc patients. Serum and Plasma concentrations of IL-6, and IL-10 correlate 
well with the MRSS in SSc (r=0.625, and r=0.663, respectively). Compared to healthy 
controls SSc patients also express higher levels of IL-1RA, IL-13, CCL2, CCL3, CCL4 
and CXCL8, but no clear associations were seen with the MRSS or other clinical 
parameters (28, 29). Other markers of B cell and T cell activation, such as B-cell 
activating factor (BAFF) and soluble cytotoxic lymphocyte antigen 4 (CTLA-4), have 
been shown to correlate with the MRSS (r=0.41 and r= 0.37, respectively)(30, 31).  
Vascular injury is another key component of the pathogenesis of SSc, and several 
biomarkers that may reflect vascular injury are elevated in SSc patients.  The naïve 
lymphocyte marker, L-selectin has been shown to correlate negatively with the 
MRSS(32). Endostatin has been shown by several groups to be elevated in SSc compared 
to controls, and in particular higher in patients with more diffuse skin disease(33, 34). 
Endostatin, however, was shown not to correlate directly with the MRSS when examined 
longitudinally (35).  
The examination of a broad spectrum of proteins in serum has historically been 
hampered by lack of efficient multiplex high throughput technology. More recently, 
proteomic analyses have begun using mass spectrometry and Luminex bead-based 
technology (36, 37). Mass spectrometry is limited due to the wide range of protein 
abundances in serum,(38) particularly the high levels of albumin(39). Luminex bead-
based technology is also limited in its level of multiplexing due to spectral overlap, which 
leads to false positives and limits the number of analytes that can be assessed.(40, 41)  
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In contrast, the aptamer-based technology that we use in the studies to be 
presented here utilizes nucleic acid-based ligands as opposed to protein-based ligands. 
This technology underlies SomaLogic’s SOMAscan assay and allows for identification of 
ligands with very low dissociation rate constants that enables a broad (in these studies 
measuring ~1150 proteins) and deep (across 8 logs of dynamic range) interrogation of the 
proteome with a small volume of sample (250uL for sera).(42) Specifically, the nucleic 
acid aptamers contain chemically modified nucleotides that mimic amino acid side 
chains. These aptamers act as highly specific protein binding reagents in a multiplexed 
assay that transforms the quantity of each targeted protein into a corresponding quantity 
of aptamer.  The aptamer is then quantified with a custom hybridization array. Thus, this 
technology has clear advantages over both mass spectrometry and to antibody-based 
multiplex platforms.  
Since taking a skin biopsy is invasive and a less invasive and more convenient 
method to monitor changes in disease severity over time would be using serum. We 
aimed to agnostically investigate the serum proteome in order to identify proteins that 
correlate with measures of disease severity. Our goal was to use the SOMAscan 
technology to guide our identification of an objective serum pharmacodynamic biomarker 
that could be utilized as supplement or in early phase clinical trials as a surrogate 
outcome measure. Furthermore, the SOMAscan technology permitted us to make an 
unbiased assessment of SSc specific regulation of pathways in the serum and plasma. 
(43)   
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Biomarkers in Pulmonary Arterial Hypertension  
There have been many publications of biochemical measures associated with 
PAH occurring in a range of contexts. However, there has been little study of SSc-PAH, 
as studies often do not include this patient population or else group SSc with other 
connective tissue disease (CTD). Since PAH biomarkers in SSc patients might be 
confounded by or secondary to co-morbid disease complications such as ILD or cardiac 
fibrosis, it is important that biomarkers of SSc-PAH are evaluated discretely.  
PAH is a vascular disease where the blood flow through the arteries in the lungs 
becomes difficult because they are narrow or blocked. This blockage results in an 
increase in the blood pressure in the lungs, the heart has to work harder, and this can 
eventually lead to heart failure. Due to this integral link between the heart and the lungs 
in the disease pathogenesis the most studied and only clinically available blood PAH 
biomarkers are markers of heart strain/failure such as brain natriuretic peptide (BNP) and 
N-terminal fragment of pro-BNP (NT-proBNP), which have similar diagnostic 
accuracy(44). Cardiovascular homeostasis is correlative to the diagnostic hemodynamic 
measurements used in PAH and natriuretic peptides are integral to this homeostasis. 
Unsurprisingly the levels of BNP and NT-proBNP have been shown to correlate with 
these hemodynamic measurements and can be used to predict disease prognosis and 
mortality (45). These tests are generally specific for SSc-PAH as compared to SSc 
without PAH but lack sensitivity (46). Unfortunately, the clinical utility of BNP and NT-
proBNP in both idiopathic and scleroderma-associated PAH is limited by their low 
sensitivity (47, 48). 
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Other groups have studied other potential biomarkers for diagnosing PAH and 
some have been shown in preliminary studies to be superior to both BNP and NT-
proBNP(49-51). Many of these other biomarkers of SSc-PAH might reflect different 
pathogenic processes than cardiovascular homeostasis. There are other pathogenic 
processes that are integral to the disease such as the effect of PAH on vascular 
remodeling, dysregulated or damaged endothelial and vascular smooth muscle cells, 
inflammation, and hypoxia. 
Biomarkers reflecting the inflammatory pathogenesis of PAH have been 
identified. C-reactive protein (CRP) is elevated compared to patients without PAH and to 
be associated with mortality and in thromboembolic disease decreases with 
treatment(52). Pentraxin 3 (PTX-3) has been shown to be a more robust inflammatory 
biomarker for PAH and CTD-PAH than CRP(51). However, this study was not limited to 
patients with SSc-PAH; only 59% of the subjects had SSc-PAH. Using a more agnostic 
approach, which looked at 89 proteins another study confirmed and extended 
inflammatory markers, showing that CRP, IL1, IL8, and TNFa are all increased in SSc-
PAH compared to SSc-without PAH (53). This study was designed specifically to assess 
SSc-PAH. The patients that were included only had limited skin disease and little other 
lung complications (SSc-ILD).  
Several markers of vascular disease and endothelial cell damage are also elevated 
in SSc-PAH. Endothelin1 (ET-1), a potent vasoconstrictor produced by vascular 
endothelial cells, is elevated in SSc-PAH compared to those patients without PAH and 
correlates with pulmonary artery pressure (PAP) in PAH patients (54). (55, 56). Current 
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treatments for pulmonary hypertension include Bosentan, which is a receptor antagonist 
for ET-1. Levels of Endoglin, normally expressed on both endothelial and vascular 
smooth muscle cells, have also been shown to be elevated in PAH and correlate with 
survival (50). The previously mentioned agnostic proteomic approach in the serum that 
showed elevation of inflammatory markers in SSc-PAH also showed intercellular 
adhesion molecule-1 (ICAM-1), vascular cell adhesion molecular-1 VCAM, and vascular 
endothelial cell growth factor (VEGF) are all elevated in PAH patients compared to 
limited no PAH patients(53).  
Even with these studies of promising diagnostic biomarkers, the small numbers of 
patients included and lack of validation studies mean that there is still no blood test to 
accurately diagnose SSc-PAH. The studies here discover and verify novel biomarkers of 
SSc-PAH that singly or in combination will permit a more accurate diagnosis to detect 
this complication earlier and more accurately guide clinical decision-making about which 
patients need right heart catheterization.  
The work presented here is innovative as currently there are no validated 
biomarkers for the diagnosis of PAH. Also this study allows for agnostic identification of 
potential biomarkers while previous studies such as the four-gene biomarker were 
developed based on previous scientific observations. This allows us to identify new 
pathways important in disease pathogenesis. In addition, this study provides a platform to 
assess potential innovative skin RNA and serum biomarkers in clinical trials in tandem 
with the utilization of a longitudinal database of SSc patient’s clinical evaluations. These 
studies take advantage of our large and well-characterized, longitudinal SSc clinical 
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database with samples collected longitudinally from over 500 patients. This database and 
associated clinical sample repository has a particularly carefully collected clinical 
information that includes patient reported outcomes. This database allows us to examine 
biomarkers in the context of clinical outcomes, like the forced vital capacity (FVC), 
MRSS and PAP, and to examine potential confounding variables, such as concomitant 
medications and diseases as well as to explore a wide variety of other clinical 
complications such as digital ulcers and scleroderma renal crisis.   
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CHAPTER TWO: DECREASED BIOMARKERS AND CLINICAL 
IMPROVEMENT IN SYSTEMIC SCLEROSIS AFTER FRESOLIMUMAB 
 Data and text used in this chapter were originally published as: Rice LM, Padilla 
CM, McLaughlin SR, Mathes A, Ziemek J, Goummih S, Nakerakanti S, York M, Fatina 
G, Whitfield ML, Spiera RF, Christmann RB, Gordon JK, Weinberg J, Simms RW, 
Lafyatis R (2015) Fresolimumab treatment decreases biomarkers and improves clinical 
symptoms in systemic sclerosis patients. J Clin Invest 125:2795-807. 
 
ABSTRACT 
Background. TGFβ has potent profibrotic activity in vitro and has long been implicated 
in systemic sclerosis (SSc); TGFβ-regulated genes show increased expression in the skin 
and lungs of SSc patients. Methods. Patients with early, diffuse cutaneous SSc were 
enrolled into an open-label trial of fresolimumab, a high-affinity, neutralizing antibody 
against all three TGFβ isoforms. Patients received two doses of 1 mg/kg fresolimumab 
(seven patients), or one dose of 5 mg/kg fresolimumab (eight patients). Serial mid-
forearm skin biopsies, performed before and after treatment, were analyzed for 
expression of TGFβ-regulated biomarker genes: Thrombospondin-1 (THBS1) and 
Cartilage oligomeric protein (COMP), and stained for myofibroblasts. Clinical skin 
disease was assessed using the modified Rodnan skin score (MRSS). Results. Skin 
expression of THBS1 declined rapidly after fresolimumab in both treatment groups 
(p=0.0313 at 7 weeks and p=0.0156 at 3 weeks). Skin expression of COMP also trended 
strongly down in both groups. Clinical skin disease decreased dramatically and rapidly 
(p<0.001 at all-time points). Expression levels of other TGFβ-regulated genes, including 
SERPINE1 and CTGF, declined (p=0.049 and 0.012, respectively) and a two-gene, 
longitudinal pharmacodynamic biomarker of SSc skin disease decreased after 
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fresolimumab treatment (p=0.0067). Dermal myofibroblast infiltration declined in skin in 
patients after fresolimumab (p<0.05). Baseline expression of THBS1 predicted 
improvement in THBS1 expression and the MRSS after fresolimumab. Conclusion. 
Rapid fresolimumab inhibition of TGFβ-regulated gene expression strongly implicates 
TGFβ in the pathogenesis of fibrosis in SSc. Parallel improvement in the MRSS indicates 
that fresolimumab rapidly reverses markers of skin fibrosis.  
INTRODUCTION 
Soon after its discovery as a transforming growth factor, TGFβ was recognized to have 
potent profibrotic activity (57, 58). TGFβ promotes collagen synthesis, secretion, 
processing and cross-linking (59), as well as secretion of other matrix molecules such as 
fibronectin and thrombospondin (60). All three TGFβ isotypes (TGFβ1, TGFβ2, and 
TGFβ3) interact with the same receptor complex, and have wide ranging, context specific 
effects on cell proliferation and differentiation, embryological processes, and the immune 
system (61).   
Fibrosis in patients with systemic sclerosis (SSc) affects the skin and also internal 
organs: lungs, heart, and gastrointestinal tract (62). It represents a major unmet 
therapeutic challenge, as treatment for SSc fibrotic disease is currently limited to modest 
effects of cyclophosphamide (63), whereas more dramatic benefit of immunoablation and 
stem cell transplant comes with significant treatment-associated morbidity and mortality 
(64). Further, fibrosis is an end-stage of many diseases, including many common disease 
such as liver cirrhosis complicating viral or drug induced hepatitis, renal fibrosis as the 
pathological feature leading to many forms of end-stage renal disease, cardiac fibrosis 
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after myocardial infarctions and associated with hypertension, and pulmonary fibrosis, 
either idiopathic or associated with a variety of other diseases or environmental exposures 
(65). Although skin disease in SSc does not cause death, extensive skin disease is 
associated with considerable morbidity and severity of internal organ disease, as well as 
disease-associated mortality (9). Skin fibrosis also shares pathogenic features with other 
sites of fibrotic disease in SSc patients, suggesting that agents successfully treating skin 
might show efficacy for other involved organs (66). As skin can be easily biopsied, it 
provides a window into understanding pathogenesis and also a methodology for assessing 
response of a target organ. 
Several factors have slowed development of therapeutics targeting fibrosis in SSc. 
The variable trajectory of disease progression in different organs in SSc patients has led 
to particular challenges in identifying efficacy in early phase clinical trials; this has 
included slow rates of progression of interstitial lung disease (67) and spontaneous 
improvement of skin disease (68). In addition, the relatively slow rate of change in skin 
disease as assessed by the main clinical outcome, the MRSS, and the relative insensitivity 
of the MRSS to change has led to the notion that changes in the MRSS require long 
periods of observation to detect. Together, these observations have led to promotion of 
large, placebo-controlled, 12-24 month clinical trials in SSc, even in the early phase of 
clinical development (69), presenting a significant obstacle for progress discovering 
effective therapeutics for SSc.  
Biomarkers that correlate with the MRSS might act as surrogate outcome 
measures for the degree of skin disease in SSc patients, and thus provide an approach for 
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more quickly detecting potential drug efficacy in early phase SSc clinical trials. 
Biomarkers can be measured objectively, and might be expected to change more quickly 
than clinical outcome measures such as the MRSS. We previously described a 4-gene, 
pharmacodynamic biomarker of SSc skin disease, based on gene expression in a mid-
forearm skin biopsy (70). Two of the four genes making up the biomarker, 
Thrombospondin-1 (THBS1) and Cartilage oligomeric protein (COMP), are highly 
regulated by TGFβ. Thus, to test the importance of TGFβ in SSc skin fibrosis, as well as 
to test a biomarker based approach to early phase clinical trial design, we treated early, 
diffuse SSc patients with fresolimumab, a first in class human IgG4 kappa monoclonal 
antibody capable of neutralizing all mammalian isoforms of TGFβ. The predefined 
primary efficacy outcomes for this trial were change in mRNA expression of COMP and 
THBS1 in skin after treatment compared to baseline.   
RESULTS 
Patients 
Patients were mostly female with a median age of 51 and median MRSS of 24 (Table 1). 
Only one patient showed signs of interstitial lung disease with a median forced vital 
capacity of 90% predicted. Four (27%) patients had anti-Scl70 and eight (53%) anti-RNA 
III autoantibodies. Anti-RNA Polymerase III autoantibodies are typically seen in only 
about 11% of all SSc patients (71), but are much more common in patients with diffuse 
cutaneous disease (72). Since anti-RNA Polymerase III autoantibodies are associated 
with more severe skin and less severe interstitial lung disease (72), our entry criteria, 
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which included only patients with diffuse cutaneous disease and excluded patients with 
significant lung disease, likely enriched for patients with this autoantibody specificity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Baseline demographic and clinical characteristics of study patients (n=15)  
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Two groups of patients were treated with fresolimumab, the first (group 1, n=7) with two 
doses of 1 mg/kg fresolimumab four weeks apart and the second (group 2, n=8) with one 
dose of 5 mg/kg fresolimumab (Figure 1A and 2A). Skin biopsies were performed at 
baseline (the day of first infusion), and at 3 weeks (group 1) or 4 weeks (group 2), 7 
weeks, and 24 weeks after the baseline biopsy (Figure 2A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. CONSORT Flow Diagram.  
Schematic showing patients screened, enrolled and completing the trial in the two study 
groups.   
		
20 
Figure 2. Study design and pharmacokinetics of fresolimumab in two dosing groups.   
Trial protocol for each group shows dosing levels and frequency, and timing of skin 
biopsies (panel A).  Panel B, Fresolimumab levels measured in sera at 3, 7, 11, 17, and 24 
weeks in group one receiving two doses of 1 mg/kg at weeks 0 and 4 (blue diamonds), 
and group two receiving a single dose of 5 mg/kg fresolimumab at week 0 (red squares).  
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Skin biomarker gene expression of THBS1 shows a rapid decline after fresolimumab 
treatment  
The two groups of patients showed dramatically different serum levels of fresolimumab, 
group 2 reaching ~five times higher serum levels three weeks after treatment than group 
1 (Figure 1B). Even after the first group of patients received a second 1 mg/kg dose of 
study medication, the relative levels of circulating fresolimumab were nearly twice as 
high in the second group (receiving a single 5 mg/kg dose) at 7 weeks and subsequent 
time points due to the circulating half-life of ~22 days.  
Both treatment groups separately showed rapid declines in THBS1 and COMP 
gene expression, the primary efficacy outcome measure (Figure 3 panels A-D, Table 2). 
Patients in the first dosing group showed a significant decline in median THBS1 
expression at seven weeks compared to baseline, 67.2% baseline (p=0.0313, Figure 3A 
and Supplementary Figure 1A), and a trend toward decreased COMP expression, 77.1% 
baseline (p=0.218, Figure 3C and Supplementary Figure 1C). Patients in the second 
dosing group showed a more rapid decrease in THBS1 and COMP, nadiring at week 
three, 70.0% baseline (p=0.0156, Figure 3B and Supplementary Figure 1B) and 66.7% 
baseline (p=0.0781, Figure 3D and Supplementary Figure 1D), respectively. Decreases in 
gene expression seen at three/four and seven weeks were lost at week 24 (Figure 3, 
panels A-D), a time when circulating fresolimumab was mostly metabolized (Figure 2B). 
However, in the first dosing group, the loss of significant change at week 24 might reflect 
the availability of fewer biopsies for analysis.  
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Figure 3. Changes in biomarker gene expression and MRSS by study group.   
Graphs show Thrombospondin-1 (THBS1, panels A and B) and Cartilage oligomeric 
protein (COMP, panels C and D) gene expression, and MRSS (panels E and F) from 
study patients in group 1 (n=7), receiving two doses of 1 mg/kg fresolimumab, (A, C and 
E) and group 2 (n=8), receiving one dose of 5 mg/kg fresolimumab (B, D and F). Dot 
plots show median and statistical significance of THBS1 and COMP gene expression 
(Wilcoxon signed rank using available data). Box plots show median, interquartile (box) 
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and 95% confidence limits (whiskers) of MRSS. Line graphs showing changes in 
individual patients over time are shown in supplementary Figure 1. 
 
 
Table 2: Gene Expression by Treatment Group  
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Changes in gene expression in study patients generally correlated with changes in 
MRSS (compare Supplementary Figure 1 panels A and C with panel E; and panels B and 
D with panel F). Examining the correlation between the MRSS and biomarkers in all 
biopsies revealed a high correlation for THBS1, r=0.63 and COMP, r=0.62 (data not 
shown), similar to correlations we reported previously between the MRSS and gene 
expression (70). Baseline THBS1 and COMP gene expression were strikingly higher in 
both SSc patient cohorts than in healthy control skin, as we have reported previously 
(Figure 2, panels a-d)(70). Median baseline values were higher in the first cohort 
(THBS1=11.63, COMP=36.84) compared to the second cohort (THBS1=5.97, 
COMP=16.20; Figure 3, panels A-D), as were median baseline MRSS values (25 
compared to 22.5, respectively). 
Summary statistics using all available data for patients entered into both treatment 
groups showed that THBS1 and COMP expression declined rapidly after fresolimumab 
treatment (Table 3). Gene expression results from skin biopsies following treatment in 
the first cohort at three weeks and in the second group at four weeks were combined for 
these analyses.  Median THBS1 levels at week three/four were 77% of baseline, reaching 
a nadir at week seven of 61% baseline THBS1 expression. Median COMP levels at week 
three/four and week seven were, respectively, 60% and 75% baseline COMP expression. 
Examining gene expression of evaluable, paired biopsies from both treatment groups, 
median THBS1 expression decreased by -1.5 (p=0.0135) and -1 (p=0.004), at week 
three/four and week seven, respectively (from baseline median of 8), and median COMP 
expression decreased by -7.9 (p=0.058) and -4.3 (p=0.153) at week three/four and week 
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seven, respectively (from baseline median of 22.6). 
 
Table 3. Summary Statistics on all available data (dosing groups combined)  
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To verify the results using an analytic method robust in accounting for “missing at 
random” data, we used a repeated measures model to take advantage of the multiple 
measurements per subject. Controlling for dose group, the predicted mean changes from 
baseline (β coefficients) closely paralleled the results obtained using all available data 
(Table 4). Changes in THBS1 and COMP expression were largest at week seven, with 
predicted decreases of -3.4 (p= 0.018) and -3.6 (p=0.135), respectively. The dose by time 
interaction terms were significant for both THBS1 (p=0.0012) and COMP (p=0.0492), 
indicating that the patterns of change over time differed by dose group. 
 
 
Table 4. Repeated-measures model results. 
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To better understand the relationship between the skin score at the biopsy site and gene 
expression, we compared gene expression of THBS1 and COMP to the local forearm skin 
score, the 0-3 score performed on the same day as the biopsy. The local skin score 
correlated highly with the MRSS, and also with both THBS1 and COMP expression 
(Supplementary Figure 2). We also examined autoantibody levels after treatment (week 
11) compared to baseline studies (Supplementary Figure 3). Anti-Scl70 autoantibody 
levels fell modestly in all patients (4/4), but this was not a sufficient number of patients to 
indicate a statistically meaningful result. Anti-RNA polymerase III (anti-Pol3) levels 
showed no consistent change, rising in some patients and falling in others. We also 
examined the effects of autoantibody status on the clinical response. The change in 
MRSS in patients showing neither anti-Pol3 nor anti-Scl70 (median change = -12) was 
higher than in anti-Scl70-positive (median change = -5) or anti-Pol3-positive patients 
(median change = -2), but these groups were too small to make a meaningful statistical 
comparison. The change in MRSS was different comparing anti-Pol3-positive (median 
change in MRSS -2) to anti-Pol3-negative patients (grouping anti-Scl70 positive patients 
with patients negative for both anti-Scl70 and anti-Pol3; mean change in MRSS = -6, 
p=0.014) at week 7, but not at week 3/4 (p=0.33). 
 Some studies have shown that longer disease duration is associated with 
spontaneous improvement in skin disease in SSc patients (73). However, in this patient 
cohort of early disease we found no relationship between the baseline disease duration 
and the subsequent change in MRSS (Supplementary Figure 4).   
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Skin disease shows rapid improvement after fresolimumab treatment 
The primary clinical outcome in this trial, the MRSS, declined rapidly in most patients, 
generally within several weeks of the infusion (Table 3). Examining the change in MRSS 
in each study group separately showed similar appearing response kinetics, with both 
groups showing rapid decreases in mean MRSS as soon as the first follow-up study visit, 
and then increasing skin scores by the week 24 study visit, apparently representing 
recurrent disease (Figure 3 panels E and F, Table 5).  
The median change in MRSS using all available data across both dose groups was 
most striking at weeks 11 and 17, -6 (p=0.0005) and -9.5 (p=0.0024), respectively (Table 
3). Many patients then showed recurrent disease, i.e, an increase in the MRSS at a later 
point in the trial. The repeated measures model reinforced the analysis of all available 
data (Table 4), with the nadir in the predicted change of -8 at week 11 (p=0.0002).  There 
was no statistically significant dose by time interaction in the repeated measures model 
indicating that the patterns of change over time in MRSS were somewhat similar for the 
two dose groups (p=0.4168). 
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Table 5: Modified Rodnan Skin Score by Treatment Group  
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Decreased expression of a co-regulated cluster of TGFβ-regulated genes and 
macrophage-associated genes after fresolimumab treatment 
To further understand the genes regulated by fresolimumab in the study patients, biopsies 
were analyzed by microarray. Clustering of these genes revealed a readily recognizable 
cluster of TGFβ-regulated genes that included both genes predefined as the primary 
outcome measures: THBS1 and COMP (Figure 4). All of the genes in this cluster were 
found to correlate highly with the MRSS (Figure 4, right column).  
 
 
Figure 4. Hierarchical clustering of skin gene expression in study patients.   
The gene cluster that includes both primary outcome measures, Thrombospondin 1 
(THBS1) and Cartilage oligomeric protein (COMP), are shown in the Treeview zoomed 
view. Samples from each study patient (n=15) are shown as columns of gene expression 
(red = high; green = low; black = intermediate level of gene expression), labeled by study 
visit, starting with the baseline biopsy followed sequentially by subsequent biopsies (top 
of figure) with a blank column between each patient. Gene names and the correlation 
between each gene and the MRSS are shown to the right and far right, respectively.  
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Genes clustering with the primary outcome measures included several genes 
regulated by TGFβ: Connective tissue growth factor (CTGF) (74), Cadherin 11 (CAD11) 
(75), NADPH oxidase 4 (NOX4) (76), Collagen X alpha 1 (COLXa1) (77), and Collagen 
XI, alpha 1 (78). We quantified expression of several TGFβ and collagen genes by RT-
PCR. CTGF, SERPINE1 and COLXa1 all declined in expression levels after 
fresolimumab compared to baseline (Figure 5, A-C).  
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We also examined the microarray expression of inflammatory genes after fresolimumab 
treatment. CD14, CD163 and MS4A4A, all genes expressed mainly in 
monocytes/macrophages, clustered together (data not shown). Expression of CD163, 
tested by nanostring trended lower after fresolimumab treatment (Figure 5D).      
 
Figure 5. Changes in gene expression before and sfter fresolimumab treatment.   
Skin biopsy RNAs were analyzed for expression of TGFβ-regulated genes: CTGF 
(CCN2, panel A), SERPINE1 (plasminogen activator inhibitor-1, panel B), and collagen 
Xa1 (panel C), or a macrophage marker (CD163, panel D) at baseline and after 
fresolimumab treatment. Levels from five healthy controls skin samples are also shown. 
Expression of CTGF, SERPINE1 and collagen Xa1 mRNA were assayed by RT-PCR; 
CD163 expression was assayed by nanostring. Statistical significance was assessed by 
Wilcoxon signed rank. 
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Decreased expression of a SSc skin pharmacodynamic biomarker after fresolimumab 
treatment 
We tested the effect of treatment with fresolimumab on a recently developed, 
multianalyte, longitudinal pharmacodynamic biomarker (2GSSc skin biomarker, L. Rice 
and R. Lafyatis, unpublished observation). This biomarker is composed of weighted 
values for THBS1 and MS4A4A mRNA expression assessed by nanostring. The 2GSSc 
skin biomarker showed reduced expression at both 3/4 and 7 weeks after fresolimumab 
treatment compared to baseline levels (Figure 6A). We compared the 2GSSc biomarker 
in samples from a clinical trial of nilotinib in SSc. This trial included very similar early 
diffuse patients with SSc (Table 6), but skin biopsies were analyzed at baseline, 6 and 12 
months. This longer time interval between biopsies would be expected to show more 
dramatic changes in the 2GSSc skin biomarker than seen in samples from fresolimumab-
treated patients, if due to the natural history of the disease. In contrast to samples from 
fresolimumab-treated patients, nilotinib-treated patients showed no significant change in 
2GSSc skin biomarker at 6 and 12 months compared to baseline (Figure 6B).     
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Table 6. Comparison of Clinical Trial Demographics   
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Figure 6. Decreased 2GSSc skin biomarker level in skin after fresolimumab 
treatment.   
Skin RNAs from patients entered into the fresolimumab trial (panel A) or a clinical trial 
of nilotinib, (panel B) were assayed by nanostring for 2GSSc skin biomarker levels in 
baseline, 3/4 and 7 weeks (fresolimumab) or at baseline, 6 and 12 months (nilotinib). 
Statistical significance was assessed by Wilcoxon signed rank.   
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Inhibition of myofibroblasts and Plasminogen activator protein-1 (PAI1/SERPINE1) in 
fresolimumab treated patients 
TGFβ stimulates fibroblast differentiation into myofibroblasts, the cell type consistently 
implicated in fibrosis in many diseases (79). Myofibroblasts are sensitive markers of SSc 
skin disease, and the intensity of myofibroblast infiltration correlates highly with the 
severity of skin disease as assessed by the MRSS (80). In several patients fresolimumab 
was associated with a particularly rapid, dramatic decline in myofibroblast infiltration of 
the deep dermis (Figure 7 panels A-C). Examining myofibroblast infiltration in al study 
patients showed a decrease at week 3/4 after treatment with fresolimumab (Figure 7D, 
p=0.022). The degree of myofibroblast infiltration changed more consistently in patients 
receiving the higher dose of fresolimumab (second treatment group, data not shown).  
 Sections were also stained for the SERPINE1 gene product, Plasminogen 
activator protein-1 (PAI-1). PAI1 has long been recognized as a target of TGFβ (81). We 
show above that SERPINE1 mRNA is highly upregulated in SSc skin and its levels are 
reduced after fresolimumab treatment. PAI-1 protein staining was also reduced in SSc 
skin (Supplementary Figure 5A). We additionally examined dermal thickness in sections 
from patients after staining with Trichrome. However, skin thickness was not found to 
change after fresolimumab treatment. (Supplementary Figure 5B). 
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Figure 7. Myofibroblast infiltration in fresolimumab treated patients.   
Sequential biopsies from patient GC17 are shown, comparing week 4 (panel B) and week 
7 (panel C) to baseline (panel A) myofibroblast infiltration (10x original magnification). 
Arrows indicate myofibroblasts. Insets show myofibroblast staining in the deep dermis 
(40x original magnification). Skin biopsies stained for smooth muscle actin were scored 
by an observer blinded to biopsy sample for intensity of myofibroblast infiltration (Panel 
D). Median values for each time point are shown as a black bar (* indicates p<0.01, 
comparing week 4 to baseline, Wilcoxon ranked-sum).  
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Baseline expression of TGFβ-regulated genes predicts response to fresolimumab 
In order to understand whether expression of some genes might predict patient response 
to fresolimumab, we examined the relationship between microarray gene expression at 
baseline to the change in expression of THBS1 at three/four and seven weeks compared 
to baseline. Thus, a negative correlation would indicate genes whose level of expression 
at baseline predicts a decrease in THBS1 expression after fresolimumab treatment.  
Clustering only genes showing correlations r<-0.6 revealed two known TGFβ-
regulated genes, ADAM metallopeptidase domain 12 (ADAM12) and fibronectin (FN), 
clustering adjacent to each other (r=-0.7 for both, Figure 8A). THBS1 also clustered with 
these genes, correlating almost as highly as ADAM12 and FN (r=0.67). Patients stratified 
dichotomously on the basis of having higher than median baseline ADAM12 expression 
were found to significantly more frequently respond to fresolimumab (decreased THBS1 
expression compared to baseline; Figure 8B, p<0.05).  
We also examined whether expression of genes might predict the observed 
change in the MRSS. Baseline THBS1 expression robustly correlated with the change in 
MRSS at 3/4 and 7 compared to baseline (r=0.68). Patients stratified dichotomously on 
the basis of having a higher median baseline THBS1 expression were found to respond 
more frequently to fresolimumab, both biochemically (decreased THBS1 expression 
compared to baseline, p<0.05, data not shown) and clinically (decreased MRSS compared 
to baseline, p<0.05, Figure 8C).    
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Figure 8. THBS1 and ADAM12 expression predict response to fresolimumab.   
Panel A, 58 genes showing correlations with the change in THBS1 expression at 3/4 and 
7 weeks compared to baseline of less than -0.6 were clustered. Baseline ADAM 
metallopeptidase domain 12 (ADAM12), THBS1 and fibronectin (FN) cluster together, 
showing strongly negative correlations with the change in THBS1 expression after 
fresolimumab treatment at 3/4 and 7 weeks. Red is higher, green lower expression. 
Pearson correlations are shown to the right. Panel B. Patients were stratified into HIGH 
(n=14) and LOW (n=14) baseline ADAM12 expression based on showing greater or less 
than median level of ADAM12 on microarray. Patients were then graphed according to 
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week 3/4 and week 7 THBS1 expression compared to baseline (Change in THBS1). 
Patient samples showing HIGH baseline ADAM12 expression showed greater decreases 
in THBS1 after fresolimumab than patients with LOW baseline ADAM12 expression 
(p<0.05, Fisher's exact test). Panel C. Patient samples were stratified into HIGH (n=14) 
and LOW (n=14) baseline THBS1 expression based on showing greater or less than 
median level of THBS1 on microarray. Samples were then graphed according to week 
3/4 and week 7 THBS1 expression compared to baseline (Change in THBS1). Samples 
showing HIGH baseline THBS1 expression showed greater decreases in MRSS after 
fresolimumab than patients with LOW baseline THBS1 expression (p<0.05, Fisher's 
exact test).  
Safety Outcomes 
The most significant adverse events were several bleeding episodes and the common 
occurrence of anemia (Table 7). Two patients developed clinically significant 
gastrointestinal bleeding from gastric antral vascular ectasia (GAVE); one with a history 
of GAVE required hospitalization (GC08), and both required transfusion. Both lesions 
were treated effectively with argon laser photocoagulation. Gingival bleeding and/or 
epistaxis were described by three patients, and two patients showed subconjunctival 
hemorrhages. Hemoglobin levels decreased by more than 10% at some point in the trial 
in 10/15 (66.7%) patients (Table 7 and Supplementary Figure 6), in most cases resolving 
without further treatment. Most anemic patients showed iron studies consistent with 
anemia of chronic disease, although several also appeared iron deficient.  
One patient (GC13) with severe skin disease, who experienced rapid 
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improvement in skin sclerosis (MRSS 37 at baseline improving to 30 at 3 weeks) after 
receiving one dose of fresolimumab (5 mg/kg), subsequently developed recurrent skin 
disease (MRSS = 35 at week 11) and developed shortness of breath 12 weeks after 
fresolimumab dosing. This patient was subsequently diagnosed with severe congestive 
heart failure and died of heart failure 10 days later. A premorbid cardiac biopsy of this 
patient showed severe cardiac fibrosis, a known complication of SSc (82).  
 
 
Table 7. Possible/probable drug-related adverse events in study patients  
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One premalignant lesion was identified, a low-grade squamous intraepithelial 
cervical lesion found on routine PAP smear 17 weeks after fresolimumab dosing, 
subsequent culposcopy showing mild dysplasia. This patient had a history of abnormal 
PAP smears, a low-grade squamous intraepithelial lesion, and a positive test for HPV 
DNA. Subsequent to the abnormal study PAP smear the patient has had two normal PAP 
smears.  
DISCUSSION 
Based on extensive in vitro and animal data, TGFβ has long been suspected as an 
important mediator of fibrosis in SSc as well as a variety of other fibrotic diseases, 
including renal, pulmonary, cardiac and liver fibrosis (83-85). However there has never 
previously been clinical data directly supporting its role in humans. Our data show that 
fresolimumab leads to a rapid decrease of TGFβ-regulated biomarker genes. The 
predetermined primary efficacy outcome measures for the trial, THBS1 expression in SSc 
skin, declined significantly in both fresolimumab treated groups, while COMP trended 
strongly toward decreased expression in both groups. In addition microarray analyses 
showed that downregulation of these genes was associated with downregulated 
expression of a larger cluster of known TGFβ-regulated genes, including NOX4 and 
CTGF, both implicated as secondary mediators of TGFβ signaling (76, 86). Included in 
this cluster were also several collagen genes, consistent with a role for fresolimumab on 
genes directly mediating fibrosis. Expression of all of the genes in this cluster was found 
to correlate with the MRSS, most with r-values greater than 0.4, suggesting that they are 
part of a cluster of TGFβ-regulated genes that appear to play a driving role in TGFβ-
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mediated skin fibrosis in SSc.  
Further supporting the pivotal role of TGFβ in SSc pathogenesis, patients treated 
with fresolimumab showed a rapid, significant decrease in MRSS, correlating closely 
with the degree and speed of decline in the skin biomarkers. Thus, the biomarker data 
strongly reinforce the clinical data, while robustly supplementing it as an objective 
measure. The rate of decline of the skin score in these patients is unprecedented in 
clinical trials of even much longer duration (73). The natural history of patients with 
early, diffuse SSc, extracting data from 7 large, placebo controlled, negative large trials 
(n=429), showed at 6 and 12 months median MRSS improvements (decreases in MRSS) 
of 2.9 and 3.4 (68). Thus much larger and more rapid decreases in MRSS were seen in 
fresolimumab-treated patients (decrease of 5.1, 6.3 and 8 at, respectively, 3/4, 7 and 11 
weeks).  
TGFβ is also known to induce myofibroblasts (79), and the intensity of 
myofibroblast staining correlates highly with the degree of skin disease (80). Thus, 
decreased staining of myofibroblasts after fresolimumab further supports the role of 
TGFβ in SSc pathogenesis, as well as the observed clinical effect on skin disease. 
Expression of genes known to be highly regulated by TGFβ, CTGF/CCN2 and 
SERPINE1/PAI1, were also lower in patient skin samples 3/4 weeks after fresolimumab, 
strongly supporting the role of TGFβ in pathogenesis and expression of these genes. On 
the other hand, skin thickness did not change significantly after fresolimumab treatment. 
Although the MRSS is designed to detect primarily changes in skin thickness, the effect 
of fresolimumab on the MRSS is thus more likely due to the effect of blocking TGFβ on 
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skin tightness and tethering. These clinical manifestations of skin tightness and tethering 
might be due more to the presence of myofibroblasts in SSc skin and to loss of 
subcutaneous fat, respectively, rather than increased skin thickness. Our data show that at 
least one of these features, myofibroblast number, changes more rapidly than skin 
thickness after TGFβ inhibition.     
Notably, the statistically significant improvements in both clinical score and 
biomarker expression observed early after fresolimumab treatment were lost by the last 
study visit (week 24), seven or eight drug half-lives after the last dose given in the first 
and second patient groups, respectively. Thus, these data further support the role of 
fresolimumab in the observed declines in MRSS and biomarker gene expression, and 
indicate a need for longer treatment in future studies. Collectively, these observations 
strongly support a key role for TGFβ in SSc pathogenesis. 
Patients treated with fresolimumab showed a trend to decrease levels of the 
macrophage/monocyte-associated genes, CD163 and MS4A4A. The latter of these genes 
is the second of two genes in the 2GSSc skin biomarker (L. Rice, R. Lafyatis, submitted). 
The change in macrophage marker genes is less dramatic (and not statistically significant 
in this small trial), but may be suggesting that TGFβ is also contributing to the 
perivascular inflammation seen in this disease. Indeed it is known to induce monocyte 
chemotaxis in addition to its anti-inflammatory properties (87), and induces TH2, TH17 
and plasmacytoid dendritic cell migration into the skin of mice with mutations found in 
patients with stiff skin syndrome that mimic dermal fibrosis of SSc (88). 
We found that THBS1 and ADAM12 expression were predictive biomarkers for 
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improvement in THBS1 expression, and THBS1 expression predictive for improvement 
in the MRSS after fresolimumab treatment. These observations suggest that patients 
might be stratified for their likely response to TGFβ inhibition on the basis of their pre-
treatment gene expression. Both THBS1 and ADAM12 are known to be induced by 
TGFβ (89, 90). THBS1 can also activate TGFβ while ADAM12 has also been shown to 
contribute to TGFβ signaling through an interaction with the type II TGFβ receptor (91). 
Notably, in recent studies ADAM12+ pericytes were shown to be progenitors of 
myofibroblasts induced after skin or muscle injury, and deletion of ADAM12+ cells 
blocked fibrosis (92). Thus, it is intriguing to consider a possible role for TGFβ in 
stimulating ADAM12+ pericytes in the generation of myofibroblasts and fibrosis in SSc 
skin.  
An earlier study of anti-TGFβ, CAT-192, in SSc failed to show any difference in 
change in MRSS between treatment groups (93). Importantly, CAT-192 targets only 
TGFβ1 (94) with a dissociation constant of 150 nM, whereas fresolimumab is a much 
higher-affinity antibody for TGFβ1, but also targets TGFβ2, and TGFβ3, with 
dissociation constants, respectively, of 2.3 nM, 2.8 nM, and 1.4 nM (Sanofi-Genzyme, 
unpublished Biacore analyses). Thus, the neutralizing activity against TGFβ2 and 
TGFβ3, or much higher target affinity may be critical in the activity of fresolimumab in 
SSc. 
Anti-TGFβ/fresolimumab/GC1008 has been tried previously in patients for 
several diseases. In patients with focal segmental glomerulosclerosis (FSGS), 
fresolimumab treatment was associated with a decline in proteinuria in some patients, 
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suggesting possible efficacy in this disease in which TGFβ is also strongly implicated in 
pathogenesis (95, 96). Like SSc, THBS1 is overexpressed in FSGS renal glomeruli (97, 
98), suggesting that it may provide a strong biomarker in other TGFβ-mediated diseases.  
Malignant mesothelioma patients (n=13) were treated with 3 mg/kg fresolimumab 
for up to 6 doses, showing little clinical effect, but also few adverse effects. One patient 
developed erythematous, verrucous papules on biopsy showing atypical kerotinocyte 
proliferation (99). In patients with malignant melanoma (n=28) or renal cell carcinoma 
(n=1), patients received up to 4 doses of 15 mg/kg fresolimumab over a period of 56 
days, 5 patients also receiving an additional 4 doses ranging from 0.1-1 mg/kg (100). 
Minor bleeding (epistaxis and gingival bleeding) was seen frequently in these patients. In 
addition, several patients developed epithelial lesions suggestive of squamous cell 
carcinoma versus keratocanthoma, more commonly seen in patients receiving higher 
doses of medication. All but one of these was ultimately diagnosed pathologically as 
keratocanthomas, and the lesions resolved spontaneously after fresolimumab treatment 
was complete, a clinical course more consistent with keratocanthoma.  
We did not see keratocanthomas in our study, however, several patients had 
epistaxis, gum bleeding or subconjunctival eye hemorrhage as reported in other studies of 
fresolimumab (100, 101). Although the incidence of GAVE in this study group was 
similar to expected in such a patient cohort, the timing and severity of these and other 
bleeding in our study patients dictates careful observation of this complication in future 
trials. Anemia in the study patients has not been reported in past trials and may be related 
to bleeding, SSc and/or its treatment. Iron studies did not clearly distinguish iron 
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deficiency from anemia of chronic disease (or both) in most patients. No patients showed 
evidence of hemolysis and most showed an inappropriate response to the anemia (low or 
normal reticulocyte counts). Most patients were also on proton pump inhibitors, known to 
block iron absorption, and severe anemia associated with GAVE, though not correcting 
with oral iron, responded promptly to intravenous iron, consistent with underlying iron 
deficiency and preexisting gastrointestinal blood loss. Thus, future studies of 
fresolimumab in SSc patients should include careful baseline evaluation for indolent 
gastrointestinal bleeding and iron deficiency. 
Despite recent studies clarifying the natural history of dcSSc as a disease that 
frequently remits spontaneously, the disease often progresses relentlessly, and is 
associated with considerable mortality through a variety of complications (102). 
Although patients do not typically die directly of skin disease, the underlying 
pathogenesis for fibrotic complications, including fatal complication of the lung and 
bowel, is likely similar. Thus, these complications may also be driven by TGFβ and 
potentially amenable to inhibition by fresolimumab. Fresolimumab has been well 
tolerated in several trials described above at higher and multiple doses. The concern for 
side effects from TGFβ inhibition needs to be carefully weighed against the prognosis of 
SSc and currently available therapeutics. Cyclophosphamide and immunoablation with 
stem cell transplant are both associated with neoplastic complications and stem cell 
transplant with considerable transplant associated mortality (64). Fresolimumab is 
potentially a safer alternative. These complications, as well as the wide array of other 
diseases associated with organ fibrosis, may also be driven by TGFβ and respond to 
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fresolimumab. Thus, fresolimumab holds promise as a potent anti-fibrotic therapeutic, 
needing further study for safety under longer-term use and for treatment of skin, lung and 
gastrointestinal tract fibrosis.  
METHODS 
Patients  
This single center study was approved by the Boston University Medical Center 
Institutional Review Board, and registered with clinicaltrials.gov identifier: 
NCT01284322 prior to patient recruitment. The study was conducted after FDA review 
under IND #110704. A Data and Safety Monitoring Board, composed of two physicians 
external to the study investigators, reviewed all adverse events.  Patients ≥ 18 years of 
age were included who had SSc (103) with diffuse cutaneous disease (4), a MRSS ≥ 15, 
and early disease as defined by first non-Raynaud’s disease symptom within 2 years 
study entry. Patients with significant pulmonary compromise (FVC less than 80% 
predicted, DLCO less than 70% predicted or >20% fibrosis on computerized chest 
tomography); recent (within 6 months of study entry) scleroderma renal crisis or elevated 
creatinine > 2.0; significant arrhythmia, unstable angina or clinical heart failure; elevated 
liver function tests > 2.5 times normal; bowel obstruction requiring hospitalization within 
3 months or malabsorption requiring parenteral nutrition; recent bleeding, anemia (Hgb < 
8.5) or thrombocytopenia (platelet count < 100,000/mm3); active infection; or any history 
of malignancy or history of premalignancy within 5 years were excluded. Patients were 
required to be on a stable dose of 10 mg/day or less of prednisone, and no other 
immunosuppressive medication. None of the patients received any immunosuppressive 
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medications before the primary outcome measures, the biomarker skin biopsies, were 
performed at week 3/4 and week 7. Five patients were started on an immunosuppressive 
during the safety follow-up: GC-02 was started on methotrexate at week 11, which was 
discontinued and the patient started on cyclophosphamide at week 17. GC-03 was started 
on mycophenolate on week 15 after study withdrawal at the week 4 visit. GC-11 and GC-
12 were started on methotrexate at week 11. GC-13 was started on methotrexate on week 
9. 
Study Design  
Patients meeting inclusion criteria on screening visit returned to the BUMC General 
Clinical Research Unit within 4 weeks. After an interim history and physical 
examination, two 3 mm skin biopsies were performed on the dorsal surface of the mid-
forearm, one biopsy immediately placed into 10% buffered formalin, the other into 
RNAlater. Study medication was then administered by IV infusion. The first cohort, 
receiving 1 mg/kg fresolimumab, returned after 3 weeks for safety laboratories and repeat 
skin biopsies at sites ~5mm from but immediately adjacent to the initial biopsies, 
followed by a repeat 1 mg/kg dose of fresolimumab at week 4. Fresolimumab was 
supplied by Genzyme (Cambridge, MA), now a subsidiary of Sanofi (Genzyme-Sanofi) 
under IND #110704 granted to the Principal Study Investigator, Robert Lafyatis. The 
second cohort, receiving a single dose of fresolimumab 5 mg/kg, returned at week 4 for 
safety laboratories and skin biopsies. Both cohorts returned for follow-up safety 
monitoring at weeks 7, 11, 17 and 24, with skin biopsies performed again at week 7, and 
optionally, if the patient was willing, at week 24 at sites ~5mm from but immediately 
		
50 
adjacent to the most recent biopsy. The modified Rodnan skin score (MRSS) was 
assessed at each study visit by the same study physician. The scleroderma modified 
health assessment questionnaire (SHAQ) was administered at weeks 0, 7 and 24.     
Safety Assessments 
Safety was assessed at each study visit using Common Terminology Criteria for Adverse 
Events v4.0. Based on FDA protocol recommendations all adverse events were 
considered related to the study drug unless there was a clear and identifiable reason or 
explanation to reject casual relation. Due to previous concerns for possible promotion of 
tumor progression by blocking TGFβ, in addition to routine physical exam, patients were 
monitored by complete skin, oropharyngeal and nasal exams, and for the second cohort 
by urinalysis for hematuria, at baseline and all subsequent study visits. A complete blood 
count with differential, an extended metabolic panel including electrolytes, and liver and 
renal function tests, were performed at each study visit.  
Skin Biomarker Measurements 
RNA was collected from skin samples and placed directly at the bedside into RNAlater. 
The skin was minced and homogenized with a Polytron homogenizer, RNA was purified 
using the RNeasy Mini Kit (Qiagen), and the concentration of total RNA measured 
(Nanodrop 1000; ThermoScientific). 200ng of RNA was used to make cDNA according 
to the Superscript II RT (Invitrogen) protocol using random primers and tested for 
THBS1, COMP, CTGF, SERPINE1, and COL10a1 levels by RT-PCR, normalizing 
values to 18S RNA and then normalizing the fold-change to the average expression of 
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RNAs from five healthy control skin samples. RNA was also analyzed by microarray on 
Affymetrix U133A2.0 microarray chips, and data normalized using the MAS 5.0 
algorithm. Gene expression values were clustered using Cluster 2.0 (104). After filtering 
for genes showing differences of greater than 200 across all samples, genes were mean 
centered, normalized, clustered by complete linkage and visualized using Java Treeview. 
Further exploratory analyses for inflammatory genes were carried out by clustering only 
genes selected on the basis of showing expression correlating with the MRSS > 0.4.    
RNA from skin biopsies was prepared and analyzed by microarray on Affymetrix 
U133A2.0 microarray chips. RNA extraction is described in the supplementary methods 
section. After filtering for genes showing differences of greater than 200 across all 
samples, genes were mean centered, normalized, clustered by complete linkage using 
Cluster 2.0,(104) and visualized using Java Treeview. All microarray data has been 
deposited in GEO: Series record GSE55036. 
 Immunohistochemical staining was carried out on formalin fixed, paraffin 
embedded sections. For antigen retrieval, slides were incubated in citrate buffer pH 6.1 
(Dako North America, Carpinteria, CA) for 20 min at 90oC. Sections were then incubated 
with a rabbit anti-PAI-1 (NBP2-13298, Novus Biologicals, Littleton, Colorado, 1:25 
dilution) or mouse anti-SMA Clone 1A4 (M0851, Dako, 1:400 dilution). After washing, 
the sections were incubated with polymer/HRP solution (K5361 Dako) and developed 
using DAB. Staining intensity was assessed by an observer blinded to the patient and 
visit, as described (80). Collagen thickness on trichrome stained slides was measured 
using a Nikon Eclipse E400 microscope and SPOT Software Advanced Version 4.5. 
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Measurements were taken on each biopsy from the dermal epidermal junction to the point 
where collagen staining disappeared.  
Statistical Analyses 
Summary statistics including the mean, median, standard deviation, and 95% confidence 
limits are reported overall and by dosing group for THBS1, COMP and MRSS scores at 
each time point and for change from baseline to each follow-up time point.  The 
Wilcoxon signed rank test was used to assess statistically significant changes in each 
outcome for all available data for both dosing groups combined and separately, and 
graphed using Prism software (GraphPad, San Diego, California). Spearman’s 
correlations were calculated to examine the relationships between gene expression and 
MRSS. 
For each outcome a general linear model for correlated data was used to 
incorporate all of the data into a single model and account for potential correlation 
between repeated measurements on an individual. This approach uses all available data 
and is robust to “missing at random” (MAR) data mechanisms. An unstructured 
covariance was used for all analyses.  Each model contained terms for dosing group, 
categorical time and their interaction.  The interaction was removed to assess the main 
effect of time. Beta coefficients and corresponding standard errors are reported. These 
analyses were performed using SASv9.3. Statistical analysis of predictor biomarker is 
described in supplementary methods.  
The difference in immunohistochemical staining intensities and autoantibody 
titers, comparing before and after in each patient, were analyzed using Wilcoxon Signed 
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Rank test. Statistical differences in the changes in skin score in patient groups showing 
different autoantibody status were compared using the Mann-Whitney test. 
For predictor biomarker identification, Pearson correlations between expression 
of each gene analyzed by microarray, and the difference in THBS1 expression at 3/4 and 
7 weeks compared to baseline, were calculated. Changes from baseline of 3/4-week and 
7-week were treated as independent values for these analyses. Genes showing 
correlations with fresolimumab-associated change in THBS1 expression of r<-0.4 or r<-
0.6 were selected for clustering. Using Cluster 2.0, genes were mean centered, 
normalized, clustered by complete linkage, and visualized using Java Treeview.  Fisher’s 
exact test was used to calculate statistical significance on a contingency table based on 
patients having higher or lower than median baseline ADAM12 expression, and having 
increased or decreased THBS1 gene expression from baseline. 
Study Approval 
The study was reviewed and approved by the Boston University Medical Campus, 
Institutional Review Board, 560 Harrison Avenue, Suite 300, Boston, MA. All subjects 
provided informed consent prior to their participation in the study.  
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CHAPTER THREE: A LONGITUDINAL BIOMARKER FOR THE EXTENT OF 
SKIN DISEASE IN PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC 
SCLEROSIS 
 Data and text used in this chapter were originally published as: Rice LM, Ziemek 
J, Stratton EA, McLaughlin SR, Padilla CM, Mathes AL, Christmann RB, Stifano G, 
Browning JL, Whitfield ML, Spiera RF, Gordon JK, Simms RW, Zhang Y, Lafyatis R 
(2015) A Longitudinal Biomarker for the Extent of Skin Disease in Patients with Diffuse 
Cutaneous Systemic Sclerosis. Arthritis & rheumatology. 
 
ABSTRACT  
Objective: The goal of this study was to define a pharmacodynamic biomarker based on 
gene expression in skin that would provide a biological measure of disease extent in 
patients with diffuse cutaneous systemic sclerosis (dcSSc) and that could be used to 
monitor skin disease longitudinally. Methods: Skin biopsies taken from a cohort of 
dcSSc patients that included longitudinal samples were analyzed by microarray. 
Expression of genes correlating with the modified Rodnan skin score (MRSS) were 
examined by nanostring for change over time, and a generalized estimating equation used 
to define and validate longitudinal, pharmacodynamic biomarkers composed of multiple 
genes. Results: Microarray analysis of genes parsed to include only genes correlating 
with the MRSS revealed prominent clusters of profibrotic/TGFβ-regulated, IFN-
regulated/proteasome, macrophage and vascular marker genes. Using genes changing 
longitudinally with the MRSS, two multigene, pharmacodynamic biomarkers were 
defined. The first was defined mathematically, applying a generalized estimating 
equation to longitudinal samples. This modeling method selected cross-sectional THBS1 
and longitudinal THBS1 and MS4A4A genes. The second model was based on a 
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weighted selection of genes, including additional genes with statistically significant 
change over time: CTGF, CD163, CCL2 and WIF1. Biomarker levels calculated using 
both models correlated highly with the MRSS in an independent validation dataset.   
Conclusion: Skin gene expression can be used effectively to monitor SSc skin disease 
change over time. We have implemented these relatively simple models on a nanostring 
platform permitting highly reproducible assays that can be applied directly to samples 
from patients or collected as part of clinical trials. 
INTRODUCTION 
The pathogenesis of systemic sclerosis (SSc) remains largely unknown. Controlled 
clinical trials for the organs most commonly affected by fibrosis, the skin and lungs, have 
been mostly negative except for a modest benefit provided by cyclophosphamide, and 
more dramatic benefit but also significant treatment-related mortality by immunoablation 
and stem cell transplant. The accessibility of skin to simple and repetitive biopsy makes it 
a particularly attractive organ for understanding pathogenesis and the effect of 
therapeutics, since it is directly involved by the disease process and can be easily sampled 
longitudinally, before and after therapeutic interventions.  
Expression of select genes assessed from a skin biopsy taken in the mid-forearm correlate 
with the degree of skin disease in patients with diffuse cutaneous systemic sclerosis 
(dcSSc), correlating with the modified Rodnan skin score (MRSS) (70). We previously 
reported a cross-sectional relationship between expression levels of four genes and the 
MRSS using multiple linear regression (70). The product of this equation correlated with 
the MRSS and, although not derived from an examination of longitudinal data, was found 
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to change over time in parallel with the MRSS in a small number of patients. Two of the 
genes in this four-gene biomarker, cartilage oligomeric protein (COMP) and 
thrombospondin-1 (THBS1), are known to be highly regulated by transforming growth 
factor-β(TGFβ whereas the other two genes, interferon-induced protein 44 (IFI44), and 
sialoadhesin (SIGLEC1) are known to be highly regulated by interferon (IFN). Genes 
were tested for this biomarker on the basis of their known regulation by these two 
cytokines, but relatively few other genes were tested. 
Gene expression profiling permits a more systematic approach to identification of 
pharmacodynamic biomarkers in SSc skin. The closer integration of clinical and 
biological outcomes also provides a much more powerful methodology for identifying 
pathogenic pathways than either in isolation. For example, it is now clear that many 
genes show altered expression in SSc compared to healthy skin. However, many of these 
alterations in gene expression are likely not central to disease pathogenesis, and the sheer 
number of them – in the thousands – makes it difficult to assess their role in 
pathogenesis. Here we utilize a novel approach to study gene expression in SSc skin, 
selecting genes on the basis of their relation to the MRSS prior to utilizing more standard 
approaches to interpreting high throughput gene expression, particularly clustering. Using 
this approach we can more clearly distinguish pathogenic mechanisms based on gene 
clusters, as well as select candidate pharmacodynamic gene biomarkers, confirming the 
validity of our earlier approach but also permitting generation of a more robust 
longitudinal pharmacodynamic biomarker for the extent of SSc skin disease.          
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MATERIALS AND METHODS 
Patients  
All skin samples and clinical data were collected under approval by Institutional Review 
Boards, most as part of a biomarker protocol at the Boston University Scleroderma 
Center, and the validation RNAs as part of a clinical trial of nilotinib at the Hospital for 
Special Surgery (Trial Registration: NCT01166139, (105)). Skin was biopsied on the 
dorsal surface of the mid-forearm, immediately placed into RNAlater and stored at -80oC 
until RNA purification.  
Statistical analysis 
Gene expression was transformed (log2) to improve normality. Pearson’s correlations 
were calculated to examine the relationships between MRSS and gene expression. Simple 
regression between MRSS and change in gene expression was visualized using the R 
package “corrgrams” (R 3.0.1) and ordered using principal component analysis of the 
correlation matrix (106, 107). Inter-Rater Reliability of gene expression data was 
assessed (R 3.0.1 package “irr”) using a two-way absolute model for intra-class 
correlation (ICC) (108). Generalized estimating equations (GEE) were used to examine 
the relation of gene expression at baseline and its change over time to the MRSS (109). 
RNA purification 
For RNA purification skin was minced and homogenized with a Polytron homogenizer, 
purified using the RNeasy Mini Kit (Qiagen), and the concentration of total RNA 
measured (Nanodrop 1000; ThermoScientific).  
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Microarray analyses 
200 ng of RNA was analyzed by microarray using standard protocols on Affymetrix 
U133A 2.0 arrays by the Boston University Microarray Core. Microarray gene 
expression data was analyzed after selecting genes correlating with the MRSS (r>0.4), 
using Cluster 3.0 (104). This parsed dataset (1,770 genes out of 22,278 genes) was 
analyzed by unsupervised clustering of genes and samples using average correlation and 
uncentered linkage. Clusters were visualized using Treeview 1.1.6 (110).  
Nanostring analysis  
For nanostring analysis 5uL of each RNA (20 ng/ul) to be analyzed was added to tubes in 
12 strip tubes. 20ul Reporter code set diluted in buffer code set solution (NanoString 
Technologies), and 5uL of the Capture Probe Set (NanoString Technologies) was then 
added to each tube. The solution was inverted to mix, centrifuged and placed in a 
thermocycler (MJ Mini; Bio-rad) overnight at 65°C. Samples were removed from the 
thermocycler and processed in the nCounter PrepStation (NanoString Technologies). 
Once complete samples were transferred to the Digital Analyzer (NanoString 
Technologies). Expression of genes was normalized to housekeeping genes (Nanostring 
nCounter).  
Initial analysis of pharmacodynamic biomarkers  
For initial exploratory studies, expression of representative genes in each cluster on 
microarray showing high correlations with the MRSS were tested in additional skin 
samples ("Discovery cohorts") from patients with dcSSc using a series of custom-
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designed Exploratory nanostrings. Gene expression based on these studies was correlated 
with the MRSS (these results are summarized in Table 8).  
Genes on Exploratory nanostrings showing expression that correlated highly and 
consistently with the MRSS were selected for further biomarker development and 
modeling by testing in a third custom-designed nanostring (SSc nanonstring 3.0) that 
included 17 putative biomarker genes (Table 9). Expression of these genes was 
normalized to the geometric mean of 18 housekeeping genes.  
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Table 8. Correlation of Gene Expression with MRSS in Discovery Cohorts  
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Table 9. Genes Tested on Nanostring 3.0  
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Biomarker model development using generalized estimating equation 
Generalized estimating equations (GEE) were used to examine the relationship between 
MRSS and gene expression in longitudinal biopsies. As previously described this 
equation can be written as: Yij=β0+βbxi0+βw(xi(j-1)-xi0)+γCFi(j-1)+εij (109). This model 
estimates the cross-sectional association of the risk factor and the outcome variable with 
(βb) between individuals, as well as the longitudinal association within subjects between 
change in risk factor and change in outcome variable with (βw) within an individual. In 
this study: Y is the observed measurement of the outcome (MRSS); x is the gene of 
interest; and CF represents potential confounders. A longitudinal model of change was 
developed using the GENMOD procedure of SAS, University Edition (Statistical 
Analysis System Institute Inc.); compound symmetry was used for all analyses. Beta-
coefficients were derived from the original dataset, which included 15 patients that had at 
least one follow up visit with the same rheumatologist where a skin was biopsied. These 
beta-coefficients were held constant and tested in the validation data set, which included 
10 patients whose skin was biopsied longitudinally at the Hospital for Special Surgery.  
Calculation of scores using pharmacodynamic models of MRSS  
2-Gene SSc Model and Weighted Model skin scores were calculated in a group of skin 
RNAs collected for a phase-I clinical trial of nilotinib. To calculate the 2-Gene SSc score 
of these samples the beta-coefficients derived from the original data set were used and 
gene expression of THBS1 and MS4a4a entered into the final correlation equation. For 
the Weighted Model, the Z-score of each gene included in the model was calculated on 
the basis of the average and standard deviation of all SSc samples. These scores were 
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added together and 15 added to maintain a positive value for all samples and more 
closely approximate values seen for clinical MRSS. 
Histological assessment of fibrosis and inflammation 
Hematoxylin and Eosin stained sections were scored by a blinded observer (RL) for the 
degree of fibrosis scoring hyalinized collagen, using a 10-point scale, similarly to how 
described previously (80, 111). 
RESULTS 
Microarray gene expression was evaluated in skin biopsies from 15 patients with dcSSc 
and four healthy controls (Supplemental 3). All but three dcSSc patients were within 3 
years of their first non-Raynaud’s symptom, one of these having limited disease for 8 
years before transitioning to diffuse disease approximately 18 months prior to biopsy.  
Genes making up the "four-gene biomarker" fall into two distinct clusters 
Genes showing expression that correlated positively with the MRSS (Pearson r≥0.4; 
1,770 of 22,278 genes) were analyzed by unsupervised clustering for both genes and 
subjects. Preselecting genes correlating positively with the MRSS gave easily 
recognizable clusters, showing related functions and plausible biological significance. 
Three of the four genes included in the original four-gene biomarker (70), COMP, 
THBS1 and SIGLEC1, were included in the clustering analysis (all correlating with the 
MRSS with r≥0.4). The fourth, IFI44, was not, showing a relatively low correlation with 
the MRSS. COMP and THBS1 clustered very closely with the MRSS (MRSS scores 
were added to the dataset before clustering), as did a significant group of other genes 
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easily recognized for their regulation by TGFβ, as extracellular matrix proteins, or as 
genes previously described upregulated in SSc skin (selected genes in this cluster are 
shown in Figure 9, upper panel, the complete cluster of genes is shown in Supplemental 
Figure 1). In particular, THBS1 and COMP clustered with matrix proteins: collagen VIII 
alpha 2, collagen X alpha 1, collagen XI alpha 1, and fibronectin, as well as secreted 
frizzled related protein 4 and wingless-type MMTV integration site family member 2 
(Wnt2), Wnt-related genes increased in SSc skin (112). Notably, the interleukin-4 
receptor gene, which correlates with the MRSS and forms part of the IL-4 and IL-13 
receptor, also clustered with these genes (113). Expression of genes in this cluster 
correlated relatively highly with the MRSS, most ranging between r=0.6 to 0.7 (Figure 
9).  
SIGLEC1 was found in a cluster with a group of other IFN regulated genes (select 
genes shown in Figure 9 and full cluster shown in Supplemental Figure 2), including 
guanylate binding protein, interferon induced transmembrane proteins 1, 2, and 3, 
phospholipid scramblase 1, interferon induced protein 35, and MHC class II DR beta. 
Additionally this cluster included genes encoding proteins mediating intracellular signals 
by interferon: STAT1 and interferon regulatory factor 7, and mediating intracellular 
signals from toll-like receptors: myeloid differentiation primary response gene 88. IFN 
and COMP/THBS1 clusters showed increased expression in many of the same patients, 
but some patients with a high skin score only showed increased gene expression in the 
IFN cluster, such as patients SD5-10, SD6-4 and SD10-22, consistent with our previous 
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report (70). The correlation of genes in this IFN cluster with the MRSS was lower than 
genes found in the COMP/THBS1 cluster, generally in the range of r = 0.45 to 0.65. 
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Figure 9. Genes clustering with components of the four-gene biomarker.   
Genes selected from genes clustering with COMP/THBS1 (top panel, see Fig. 1s for all 
genes in this cluster) and SIGLEC1 (bottom panel, see Fig. 2s for all genes in this cluster) 
after unsupervised clustering of genes and subjects after selection of genes showing a 
correlation with the MRSS ≥ 0.4. The MRSS added into the gene set before 
normalization and clustering appears in the heatmap of the COMP/THBS1 cluster, with 
the numerical MRSS values show in “SKIN SCORE” between the two clusters. Four-
gene biomarker genes are highlighted in yellow (COMP, THBS1, and SIGLEC1). 
Subjects (25 SSc patients and 4 healthy controls) analyzed are shown at the top of the 
figure. Red indicates up-regulated expression, green indicates down-regulated expression.  
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Another profibrotic gene cluster shows multiple TGFβ-regulated genes 
Another cluster immediately adjacent to the COMP/THBS1 cluster contained many 
additional recognizable TGFβ-regulated genes (Figure 10A, and complete cluster shown 
in Supplemental Figure 3). Several of the genes in this cluster have been found 
upregulated in SSc, such as serpin peptidase inhibitor (70), connective tissue growth 
factor (74, 114), fibronectin, collagen, type IV (115), and insulin-like growth factor 
binding protein 3 (116). Also found in this cluster are lysyl-oxidase, type 2 (LOXL2), a 
gene promoting collagen cross-linking and recently implicated in pathological fibrosis 
(117), and WNT1 inducible signaling protein (WISP1), a Wnt inhibitor upregulated in 
SSc (112). The correlation of these genes with the MRSS was relatively high, similar to 
that seen in the COMP/THBS1 cluster.  
A cluster of genes associated with MHC class I, proteasome and antigen processing 
Immediately adjacent to the cluster of IFN-regulated genes described above, another 
cluster of genes was easily recognizable containing almost exclusively genes associated 
with MHC I and antigen processing (MHCI/Proteasome cluster, Figure 10B). MHC class 
I molecule upregulation in this cluster was accompanied by increased expression of 
tapasin, proteasome 26S subunit, non-ATPase, 9 (PSMD9/LMP2), PSMD10 (LMP10) 
and proteasome activator subunit 2 beta (PA28b), all known to be strongly upregulated 
by IFNg (118), but also by type I IFNs (119-121). Several patients are discrepant between 
this and the SIGLEC1/IFN cluster (Figure 9), for example patient SD05-4, showing 
higher expression in the MHCI/proteasome cluster and SD10-20, showing higher 
expression in the SIGLEC1/IFN cluster.  
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Figure 10. Additional profibrotic and proteasome gene clusters.  
Genes selected from genes clustering with PAI1 (serpin peptidase inhibitor, clade E) and 
CTGF (connective tissue growth factor) are shown in the Profibrotic II cluster (panel A) 
after unsupervised clustering as in Figure 1. Genes selected from genes clustering with 
major histocompatibility complex, class I are shown in the MHCI/proteasome cluster 
(panel B). Pearson correlations are shown to the left of each gene.  
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Macrophage-associated genes overlap with IFN-regulated genes 
Another relatively easily identifiable cluster of genes included macrophage markers, most 
distinctly CD163 and macrophage scavenger receptor 1 (selected genes, Figure 11A; and 
complete cluster, Supplemental Figure 4). Immediately adjacent, another cluster showed 
macrophage and IFNg related genes (Figure 11B and supplemental Figure 5). We have 
recently shown that two genes found in this cluster, IL-13 receptor alpha 1 (IL13RA1) 
and interferon gamma receptor 1 are found primarily on circulating monocytes and are 
associated with limited cutaneous SSc patients who have pulmonary arterial hypertension 
(53). Included in this cluster are also genes found associated with IFN: gamma-associated 
protein 16 and phospholipid scramblase 1, emphasizing the close relationship between 
this upregulated macrophage marker and IFN-regulated genes. Immediately adjacent to 
this cluster was another cluster that contains chemokine (C-C motif) ligand 2 (CCL2, 
Figure 11B). These results are thus consistent with our recent observations that IL13RA1 
and CCL2 correlate highly with the MRSS, showing r = 0.711 and 0.792, respectively 
(113). 
Vascular marker genes cluster together 
A cluster of genes associated with endothelium was also easily identifiable (Figure 11C, 
full cluster shown in Supplemental Figure 6). Upregulated von Willebrand factor is a 
marker of vascular disease in SSc sera (122). Other well-known markers or products of 
endothelial cells were also found in this cluster: P-selectin, angiopoietin-2, intracellular 
adhesion molecule 2, plexin D1 and junctional adhesion molecule 2. The correlation of 
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these markers of endothelial cells with the MRSS was lower than seen in several of the 
other clusters, typically between 0.45 and 0.5. 
 
Figure 11. Macrophage and vascular gene clusters.  
Selected genes from a cluster of genes showing recognizable macrophage (panel A), 
macrophage and IFNg-regulated genes (panel B), and genes associated with endothelium 
(Panel C) after unsupervised clustering as described in Figure 9. Genes selected from 
genes clustering with major histocompatibility complex, class I are shown in the 
MHCI/proteasome cluster. Pearson correlations are shown to the left of each gene. 
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Development of nanostring based skin biomarker  
We tested expression of genes correlating most highly with the MRSS in each of the 
families described above using several "Exploratory" nanostring constructs containing 
TGFβ or interferon-regulated genes, and genes found in the MHC class I/proteasome, 
Macrophage and Vascular clusters. The nanostring platform permitted multiplex analyses 
and showed higher reproducibility than RT-PCR (data not shown). On repeat testing in 
skin biopsies from more patients, some of the genes analyzed continued to correlate 
highly with the MRSS, whereas others correlated less highly on repeat testing and were 
dropped from serial nanostring constructs (Supplemental Table 8).  
On the basis of these results we constructed a more refined nanostring (SSc 
nanostring 3.0,  Table 9) and tested a much larger array of skin biopsies including both 
biopsies from patients with longer standing disease and patients with longitudinal 
biopsies (Table 10). Many of the genes identified in our microarray and exploratory 
nanostring studies again correlated highly with the MRSS (Figure 12). Surprisingly, the 
disease duration did not significantly affect the correlations for most genes analyzed, and 
the correlations actually trended higher in biopsies from patients of longer disease 
duration for many genes (Figure 12). WIF1 correlated negatively with the MRSS, 
although this correlation was less robust in biopsies from patients with longer disease 
duration.      
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Table 10. Demographic and Clinical Features of Patients Studied  
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Figure 12: Relationship between expression of biomarker genes and the MRSS.  
Correlations (Pearson’s) between nanostring mRNA skin gene expression and the MRSS 
in skin biopsies from patients with dcSSc (n=63). Values are stratified according to 
disease duration at time of biopsy; blue squares ≤ 24 months, pink squares ≤ 36 months, 
and open circles ≥ 37 months. Data are shown as R-values.  
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We compared change in gene expression with MRSS and other clinical features and 
depicted these by a correlation matrix, which displays patterns of linear dependence 
among variables (Figure 13A). There was high linear dependence between TGFβ-
regulated genes: THBS1 and CTGF and between macrophage related genes: CD163 and 
MS4A4A.  
Statistically modeling a longitudinal, pharmacodynamic biomarker for SSc skin disease 
In order to define a skin gene biomarker that could be used in clinical and clinical trial 
settings, we examined both the relationship of gene expression to the MRSS cross-
sectionally between patients, and longitudinally within individual patients. These data 
showed that several genes correlated more significantly with changes in the MRSS 
longitudinally, than with the MRSS cross-sectionally (Figure 13B, compare longitudinal 
and cross-sectional p-values, see Table 11 for beta coefficients and confidence intervals).  
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Figure 13: Comparisons of gene expression in longitudinal skin biopsies from dcSSc 
patients with MRSS.  
Panel A shows the pairwise correlation matrix of clinical characteristics and absolute 
change in mRNA gene expression from baseline. The color indicates direction of 
correlation (red= negative, blue= positive); the magnitude of the correlation is indicated 
by the percentage of the filled circle and intensity of shading. Variables are ordered using 
principal components analysis. Panel B shows the significance of association cross-
sectionally and longitudinally of baseline gene expression and change in gene expression 
with MRSS values indicated in each graphic are p-values with beta coefficients and 
confidence intervals in Table 11. Each color represents an individual patient followed 
over multiple visits.  
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Table 11. Analysis of GEE Parameters-Empirical Standard Error Estimates  
 
 
 
Table 12. Demographics of Model Development and Validation Cohorts  
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Using all available nanostring data, we developed two models for assessing changes in 
MRSS over time. We first developed a model based purely on mathematical criteria using 
a generalized estimating equation. This model estimates the association cross-sectionally 
between the risk factor (baseline gene expression) and the outcome variable (MRSS) with 
one beta coefficient, as well as the association longitudinally with a second beta 
coefficient. Each available gene was tested individually for significance of cross-
sectional and longitudinal beta coefficients (Table 11). CCL2, CD163, COMP, CTGF, 
IGFBP3, IL13RA1, MS4A4A, THBS1 and WIF1 had highly significant longitudinal beta 
coefficients (p<0.015) and were then modeled in combinations. Comparing models, 
THBS1 and MS4A4A combined to give the best longitudinal regression equation:  
MRSS=-27.6844+[4.46(baseline THBS1)]+[5.31(ΔMS4A4A)+4.96(ΔTHBS1)]. 
Thus, the beta coefficient for THBS1 at baseline estimates the cross-sectional 
association between that biomarker and MRSS between individuals, whereas the beta 
coefficient for change of THBS1 and MS4A4A represent longitudinal associations 
between change in each biomarker and the change in MRSS within an individual. We 
refer to this as the 2-gene SSc skin biomarker or 2GSSc 
Using the gene expression data to calculate the biomarker predicted skin score 
showed that it correlated highly with the clinical MRSS (Figure 14, R=0.743, p≤0.0001). 
To further validate this model in an independent dataset we calculated the predicted skin 
score in skin RNAs collected from another institution (comparison of patient clinical 
features see Table 12). Again the 2GSSc skin biomarker score correlated highly with the 
observed MRSS (Figure 14, R=0.810, p≤0.0001). We examined reproducibility of this 
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technology by examining gene expression in concurrent adjacent biopsies in 5 patients. 
These analyses showed very high intraclass correlations for THBS1 (0.966) and 
MS4A4A (0.951).   
Weighted modeling a longitudinal, pharmacodynamic biomarker for SSc skin disease 
The purely statistical 2GSSc skin biomarker included only 2/9 genes we had identified as 
changing longitudinally with p<0.015 in GEE equation. Therefore, we also constructed a 
Weighted Model that would include more genes. Genes were selected that clustered 
separately but correlated significantly, longitudinally with the MRSS (Figure 12). Using 
Z-scores to quantify differences in levels of expression (see Supplemental methods), we 
constructed the following expression: 
MRSS=(THBS1+CTGF+CCL2+CD163+MS4A4A-WIF)+15. 
Calculating the predicted MRSS based on the dataset used to derive this Weighted 
Model (WSSc skin biomarker) is thus similar to calculations of IFN signature score used 
in systemic lupus erythematosus (123). Scores derived using this model also correlated 
highly with the clinical MRSS (Figure 14, R=0.688, p=0.0002). We further validated this 
model in an independent dataset where the WSSc skin biomarker also correlated highly 
with the observed MRSS (Figure 14, R=0.794, p≤0.0001).  
2GSSc and WSSc skin biomarkers correlate with histological features of skin. 
To provide an additional anchor to the 2GSSc and WSSc skin biomarkers, we examined 
the relationship between biomarker expression, and fibrosis and inflammation assessed 
histologically on biopsies taken in parallel from adjacent skin on the same day. These 
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results showed that the MRSS correlated moderately well with both skin fibrosis and 
inflammation (Figure 14E). The 2GSSc and WSSc skin biomarkers also correlated 
moderately with fibrosis and inflammation, almost as strongly as the MRSS. 
Surprisingly, macrophage markers CD163 and MS4A4A correlated only weakly with 
histological inflammation, suggesting that the cells most associated with the MRSS are 
not the same quantitatively as the perivascular inflammatory cells typically seen by 
routine histology. 
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Figure 14: Testing and validation of 2GSSc and Weighted Models.  
Graphs show correlations between 2GSSc biomarker score derived using the 2GSSc 
Model equation (panels A: p<0.0001 and B: p<0.0001) or the WSSc biomarker score 
using the Weighted Model equation (panels C: p=0.0002 and D: p<0.0001) and the 
clinically assessed MRSS. Values used to develop the models are from Boston Medical 
Center patients (panels A and C). Values used to validate the models are from Hospital 
for Special Surgery patients (panels B and D). R-values are indicated on each panel. 
Panel E. Histological features of skin were scored and compared to the MRSS, the 2GSSc 
biomarker score, the WSSc biomarker score, or genes making up the biomarker scores 
(THBS1, ADAM12, CCL2, CD163, CTGF, MS4A4A, and WIF1). Correlations between 
histological fibrosis and inflammation are charted in the corrgram with R-values as 
shown, The extent and shading of blue indicates the degree of positive correlations, the 
extent and shading of red the degree of negative correlations.     
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DISCUSSION 
 
The main goal in our studies of biomarkers has been to identify a pharmacodynamic 
biomarker that could be effectively implemented into clinical trials to provide 
supplementary information to the MRSS and other skin outcomes regarding drug 
efficacy. For a biomarker to fulfill this role it needs to change with change in a validated 
clinical outcome, in this case the MRSS. The current study confirms that THBS1 alone is 
a very strong pharmacodynamic biomarker, and presently the most reliable single 
pharmacodynamic biomarker based on the consistent observation of its high correlation 
with the MRSS in multiple datasets and, in particular, its performance in a recently 
completed trial of anti-TGFβ, fresolimumab (124).   
TGFβ regulates THBS1 mRNA expression in vitro and it clusters tightly with 
other TGFβ-regulated genes. TGFβ activation and its effect on dermal cells likely 
represent a step directly in the pathway leading to fibrosis and resulting clinical 
manifestations. This feature is key for performance of THBS1 as a pharmacodynamic 
biomarker, since biomarkers that are not directly part of the pathogenic pathway might be 
affected by ineffective therapeutic interventions. In addition, the effect of TGFβ on 
THBS1 most likely represents a step relatively distal in the pathogenic process, discussed 
further below. Detecting events distal in pathogenesis is also important for a 
pharmacodynamic biomarker, as effective therapeutics targeting pathogenic events 
downstream from the biomarker will remain undetected by the biomarker.     
We propose to continue to validate two pharmacodynamic biomarker constructs 
in ongoing and planned clinical trials. Our calculated biomarker, 2GSSc biomarker score, 
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is constructed solely on mathematical considerations. MS4A4A is a macrophage marker 
closely related structurally to CD20 seen on B cells. It clusters with other macrophage 
markers but modeling shows it as a more robust longitudinal biomarker than other 
macrophage markers, and the addition of other genes to the model does not add statistical 
significance. We propose a second model, WSSc biomarker score, to include a broader 
array of genes that correlate with changes in the MRSS. This may be better from the 
standpoint of not relying on only two measures and also because it captures more of the 
pathways and gene clusters that might drive pathogenesis. Both of these composite 
biomarkers validated an independent cohort of samples collected from a different 
institution. 
There are limitations to these biomarkers. Serial change in forced vital capacity, 
measures of vascular severity (such as digital ulcers, pulmonary arterial hypertension), 
and other clinical outcomes might be associated with different gene expression patterns. 
Although recent data argue that MRSS often peaks within 18 months, our data indicate 
that the correlation between the biomarkers and the skin score extends over 36 months or 
even longer. These observations suggest that, although skin scores begin to abate, there 
may be continuing disease activity, manifest as continuing alterations in skin gene 
expression.   
Parsing out and clustering only genes whose expression correlates with the MRSS 
provided some novel insights into pathogenesis. Most prominently and correlating most 
strongly with the MRSS, two clusters show profibrotic genes, most known to be 
regulated by TGFβ and many previously implicated in SSc pathogenesis: 
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thrombospondin1, cartilage oligomeric protein 1, connective tissue growth factor, 
cadherin 11, fibronectin and collagens type IV, VIII, X, and XI. Since matrix proteins 
directly contribute to skin thickening and these genes correlate most highly with the skin 
score, we speculate that regulation of these genes is very close to the final step in SSc 
pathogenesis. 
Two clusters of genes are highly enriched in IFN-regulated and/or proteasomal 
genes. Although the relative roles of type I and type II IFNs in SSc remains enigmatic, it 
is notable that proteasomal genes cluster discretely, suggesting the possibility that both 
IFN types might be activating gene expression and involved in pathogenesis. IFN 
regulated genes also appear in one of two prominent clusters of macrophage regulated 
genes. The other cluster contains well -known macrophage markers CD14, also a 
prognostic biomarker for progressive skin disease (125), and CD163.  
Perhaps most exciting in this clustering paradigm is the appearance of genes 
found expressed mainly by endothelial cells. We hypothesize that these genes are 
markers of vascular injury, since von Wilebrand factor is upregulated in many diseases 
associated with vascular injury (126, 127). Many studies and clinical observations 
suggest that autoinflammatory pathways trigger vascular injury and fibrosis. The 
observed clusters highlight macrophage driven and vascular injury pathways but do not 
clarify primacy. The lack of prominent T cell signature(s) is notable, but suggests that T 
cell influences occur early and transiently in SSc or are not a major factor in the skin. 
Together these results provide a strong paradigm for SSc pathogenesis, indicating the 
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altered gene expression in inflammatory and vascular cells drives connective tissue gene 
expression and fibrosis. 	  
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CHAPTER FOUR: LOCAL SKIN GENE EXPRESSION REFLECTS BOTH 
LOCAL AND SYSTEMIC SKIN DISEASE IN PATIENTS WITH SYSTMEIC 
SCLEROSIS 
 Data and text used in this chapter were originally published as: Rice LM, Stifano 
G, Ziemek J, Lafyatis R (2015) Local skin gene expression reflects both local and 
systemic skin disease in patients with systemic sclerosis. Rheumatology. 
 
INTRODUCTION 
The extent of skin disease in patients with systemic sclerosis (SSc) is typically measured 
using the modified Rodnan skin score (MRSS). Skin involvement at 17 sites is scored 
from normal to severely thickened skin (0-3) and the sum of all 17 sites is defined as the 
MRSS (0-51). It has been shown that an increase in MRSS (MRSS≥20) correlates with 
internal organ complications and increased risk of mortality and a decrease in MRSS 
correlates with improved survival(9, 10). Skin is easily biopsied and provides insight to 
other sites of fibrosis and information about therapeutic response(66). We have shown 
previously that expression of certain biomarker genes in skin biopsies taken from the 
mid-forearm of SSc patients correlates highly with the MRSS(12, 113). However, it 
remained unclear whether the success of such an approach represented a particularly 
accurate, molecular quantification of local forearm skin disease or a manifestation of 
altered gene expression known to occur in all the skin of SSc patients(128).  	  
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MATERIALS AND METHODS 
RNA purified from dorsal mid-forearm skin biopsies from 42 patients with SSc(129) and 
five healthy controls (HC) was analyzed using a custom nanostring (Nanostring 
nCounter), constructed to measure 17 genes selected from previous gene expression 
studies(12, 113, 125). All skin samples and clinical data were collected under approval by 
Institutional Review Boards, as part of a biomarker protocol at the Boston University 
Scleroderma Center. There were 18 housekeeping genes were included for normalization 
purposes. Patient characteristics were as follows: average age, 51 years (SD=11), HCs 44 
years, SD=15; female, 71% (HC 80%); average MRSS, 22 (SD=12). The average disease 
duration, 28 months (SD=25), with 100% having diffuse cutaneous skin involvement as 
defined by skin involvement proximal to forearms or legs, and 81% classified as early 
dcSSc (≤36 months from first non Raynaud’s symptom). Gene expression was 
transformed (log2) and any difference between categories of forearm scores assessed 
using a one-way ANOVA, with a posttest for linear trend. MRSS was treated as a 
continuous variable and correlated (Pearson’s) with gene expression.  
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Figure 15: Forearm and MRSS scores correlate with gene expression.  
Genes were assessed for difference between local forearm score (ANOVA), significance 
is represented by: * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001. Annotated on the 
graphs are R squared values for forearm skin score (posttest for linear trend) and MRSS 
(Pearson’s). Dotted lines indicate mean and standard deviation of healthy controls for 
each gene. Genes shown: thrombospondin-1 (THBS1), cartilage oligomeric protein 
(COMP), chemokine ligand 2 (CCL2), interleukin 13 receptor alpha 1 (IL13RA1), cluster 
of differentiation 14 (CD14), and cluster of differentiation 163 (CD163). 
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RESULTS 
All 17 putative biomarker genes were expressed significantly higher in SSc patients than 
healthy controls (FDR corrected p<0.05), with the exception of WIF1, which was 
expressed at a significantly lower level in SSc patients (FDR corrected p<0.05). 
Expression of genes was significantly different across groups based on forearm score 
(Figure 15). TGFβ-associated genes (CTGF, SERPINE1, ADAM12, THBS1, COMP) 
were consistently different across groups (p<0.0001) and correlated moderately to 
strongly with both the local score and the MRSS (0.80≥r≥0.40). THBS1 correlated 
strongly (r=0.76:p<0.0001), while COMP correlated moderately (r=0.63:p<0.0001) with 
the local skin score (Figure 15A). These same genes also correlated with the MRSS 
although not to the same extent as the forearm score (Figure 15A). Conversely, CCL2 
and IL13RA1 correlated more strongly with the MRSS (r=0.65:p<0.0001; Figure 15B) 
than the forearm score (r=0.47:p=0.0005, difference in means p<0.01). Macrophage 
associated genes MRC1, MS4A4A, CD14, CD163, SIGlLEC1, although elevated, 
correlated only weakly with the local skin score and MRSS (representative CD14 and 
CD163 r≤0.36:p=0.003 shown in Figure 15C, difference in means p<0.05). Several other 
genes examined correlated moderately: THY1 (r=0.42), IGFBP3 (r=0.50) and IFITM3 
(r=0.42) or weakly: WIF1 (r=-0.33), and IFI44 (r=0.2) with the local skin score. 
DISCUSSION 
The different relationships between local gene expression and local versus 
systemic assessment of the skin (MRSS) suggest a hierarchy of molecular events. TGFβ 
is highly implicated directly in skin fibrosis, and expression of TGFβ regulated genes 
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(THBS1, COMP) correlated most highly with the local skin score. Thus, these genes may 
represent molecular events closest to local clinical manifestations. This is unsurprising, as 
in previous studies COMP and THBS1 expression correlate more strongly with MRSS in 
lesional than in non-lesional skin(12). Expression of other genes (CCL2, IL13RA1) that 
correlate more closely with the MRSS than local forearm skin score may reflect more 
generalized immune dysfunction that is driving systemic pathogenesis. IL13 is an 
immune system derived mediator of fibrosis, and regulates CCL2(113). Using CCL2 as a 
marker of early disease is further supported here, by the observation that CCL2 was the 
only gene in which the majority of patients with a forearm skin score of zero had gene 
expression above one standard deviation of healthy controls. Altered gene expression that 
does not correlate with the skin score (CD14, CD163) may represent molecular events 
earlier in the pathogenic cascade. This is consistent with earlier work suggesting that 
CD14 is a prognostic biomarker for SSc(125). Alternatively those genes that do not 
correlate with clinical scores might represent epiphenomena without direct roles in 
pathogenesis. As the forearm skin score correlated strongly with the MRSS in this cohort,  
(r=0.86) upregulated expression of some genes in SSc skin, such as THBS1 and COMP, 
potentially could be used as biomarkers for clinical trials of drugs delivered by local 
topical application. 
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CHAPTER FIVE: PROTEOME DERIVED PHARMACODYNAMIC 
BIOMARKERS FOR DIFFUSE SYSTEMIC SCLEROSIS SKIN SHOWS TGF-
BETA AND INNATE IMMUNE PATHWAYS 
Abstract  
In this study we aimed to agonistically investigate alterations in the serum proteome of 
patients with diffuse cutaneous systemic sclerosis (dcSSc), and identify differentially 
expressed proteins that correlate with disease severity. Our goal was to identify a 
combination of serum proteins that would provide a biological measure of extent of skin 
disease and potentially be used as a pharmacodynamic (PD) biomarker. Sera analyzed by 
SOMAscan aptamer technology, from two cohorts of dcSSc patients were used to 
identify analytes as both differentially regulated, as well as correlated with MRSS. This 
dataset allowed us a so far unique opportunity to examine potential upstream regulators 
of the serum protein patterns in scleroderma serum. ELISAs were used to test proteins for 
validation. The combination of two analytes (ST2 and Spondin-1) was used to describe 
longitudinal change. This model was then validated in three independent cohorts. In this 
study we have discovered that several proteins not previously associated with SSc, are 
upregulated in patients’ sera and correlate with the extent of skin disease. Furthermore, 
we have developed a PD biomarker based on levels of two proteins and show that this 
biomarker can be applied to assess changes in skin disease in dSSc patients over time.  
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Introduction: 
Systemic Sclerosis (SSc) is a multisystem disease characterized by largely 
untreatable fibrosis and highly variable disease progression. Due to this variable disease 
progression, molecular and clinical methods to identify objective therapeutic response 
measures have remained elusive.(130) The most broadly accepted outcome measure for 
extent of skin disease in clinical trials is physical examination of the skin quantified by 
the modified Rodnan skin score (MRSS).(131) We have recently described a 2 Gene Skin 
mRNA biomarker (132) that can be used to monitor SSc skin disease change over time 
with the MRSS. However, this outcome requires skin biopsies. Thus, identification of 
pharmacodynamic serum biomarkers that correlate with changes in skin disease would 
provide a less invasive and more convenient method to monitor changes in disease 
severity longitudinally. Serum samples represent an opportune source for following 
disease activity as blood is readily accessible and comes in contact with the surrounding 
tissues.(133)  
Serum autoantibodies, which are present in greater than 95% of SSc patients, have 
historically been used for clinical diagnosis of SSc and to predict specific clinical 
manifestations of SSc.(134) Autoantibody specificities define the risk and severity of 
certain complications, for example, anti-Pol3 is associated with more severe skin disease 
and SSc renal crisis, while anti-Scl70 is associated more commonly with ILD. Anti-
topoisomerase I titers were shown to correlate with MRSS, both longitudinally and cross-
sectionally in a subset of patients with positive autoantibody titers.(135) This finding was 
validated in part by a second study, which showed that anti-topoisomerase I correlates 
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with the MRSS cross-sectionally, however longitudinal data in this study showed no 
correlation between changes in MRSS and changes in anti-topoisomerase I.(136) Another 
study found a weak correlation between anti-Pol3 titers and change with MRSS.(137) 
However, in most cases autoantibody titers do not appear to correlate with changes in 
disease severity and thus cannot be used as markers of disease activity or drug responses. 
Previous studies using serum samples have generally been limited to examining 
the correlations of single or relatively small groups of proteins with the MRSS in order to 
identify them as potential biomarkers of disease progression.(28, 133, 138-140) One 
study first investigating the proteome of plasmacytoid dendritic cells to inform the 
selection of proteins found that circulating CXCL4 correlated very highly with MRSS 
cross sectionally.(140) However, this study did not examine whether CXCL4 changes 
longitudinally with the MRSS.(131) Several previous studies have investigated particular 
proteins longitudinally, including cartilage oligomeric protein (COMP), for which the 
concentrations have been shown to parallel changes in MRSS.(24) In two other separate 
studies serum Periostin and IL-33 levels were examined in a longitudinally and shown to 
parallel disease duration and changes in MRSS.(139, 141) Serum samples have also been 
incorporated as secondary outcome measures in SSc clinical trials.(93, 142) In the CAT-
192 trial Procollagen I Intact N-Terminal (PINP) a serum marker selected for its collagen 
biosynthesis properties was found to correlate with MRSS.(93) A caveat of these cross 
sectional and longitudinal studies is that they were directed investigations of specifically 
chosen proteins, and they have not been validated in other cohorts or shown to change 
with MRSS longitudinally.  
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Only a few prior studies have examined broader arrays of serum markers. The 
first investigated 30 circulating markers to define a 17-analyte-biomarker model that was 
able to predict a diagnosis of SSc. Within these 17 markers a core of six analytes (TNF-
RII, IFN-y, IP-10, RANTES, HGF, and MIG) were found as the major contributors to the 
classifier, several of which were novel.(37) More recently a study using surface-enhanced 
laser desorption ionization time-of-flight mass spectrometer (SELD-TOF-MS), identified 
25 differentially expressed proteins between healthy controls and SSc patients.(143) Of 
particular interest S100A8/A9 was elevated in limited cutaneous SSc patients and 
correlated with lung fibrosis. A recent anti-IFNAR1 trial in SSc examined 93 serum 
proteins using the Luminex bead based technology. (36) Several proteins were found to 
be correlated with clinical measures such as MRSS, including PRDX4 as well as some 
extra cellular matrix associated proteins such as TIMP1 and SPP1. Furthermore, several 
biologically relevant proteins were reduced with the administration of treatment although 
there was not a significant decrease in the MRSS. 
In this study, we both investigated the serum proteome in patients with diffuse 
cutaneous SSc (dcSSc) to identify proteins that correlate with disease severity cross-
sectionally and longitudinally. We assessed serum samples using the SOMAscan 
technology, which detects 1149 proteins, thus including a broader subset of proteins than 
other available technologies and permitting an assessment of SSc-regulated pathways. 
(43) Next, through a series of validation cohorts, we identified markers that reflected 
change longitudinally and developed a multianalyte model that changes with changes in 
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the MRSS over time, thus providing a validated serum biomarker for use in trials of skin 
disease in SSc.  
Results: 
High throughput protein expression 
Somascan protein expression was evaluated in sera from twelve patients with diffuse 
cutaneous Systemic Sclerosis (dcSSc) and four healthy controls (Demographics in Table 
13). All dcSSc patients were within two years of their first non-Raynaud’s symptom.  
Forty-three proteins were identified as both differentially regulated in dcSSc patients 
compared to healthy controls, as well as correlated with the MRSS. To enable a more 
robust selection of proteins, after adjusting for multiple comparisons, the p-values of 
differential expression between controls and SSc patients were combined with the p-
values for the correlations with the MRSS   (Fischer’s method FDR<0.02). Analytes 
meeting these criteria were analyzed by unsupervised clustering for both proteins and 
subjects (Figure 16).  
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Table 13. Baseline Demographics of Somalogic and Cross-Sectional ELISA Patients 
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Figure 16: Hierarchical clustering of sera protein expression in dcSSc patients  
  
43 analytes analyzed by unsupervised clustering that were identified again as 
differentially regulated in dcSSc patients (n=14) compared to healthy controls (n=4), as 
well as correlated with MRSS (FDR<0.02). Here, red and blue indicate high or low 
expression; Group 2 indicates healthy controls and Group 1. 
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Somascan assays were repeated on a second, larger cohort including 20 dcSSc patients 
and 11 healthy controls (Demographics in Table 13). All dcSSc patients were within two 
years of their first non-Raynaud’s symptom. 237 analytes were identified again as 
differentially regulated in dcSSc patients compared to healthy controls, as well as 
correlated with MRSS combined by Fischer’s method (FDR<0.02). These analytes were 
analyzed by unsupervised clustering for both proteins and subjects, showing a clear 
delineation between dcSSc patients (group 1) and healthy controls (group 2; Figure 17). 
Between the two cohorts there were 760 proteins with a FDR<0.1, 301 from the first 
(smaller) cohort and 459 proteins from the second cohort. There was substantial overlap 
between proteins identified as significant in the two cohorts with 61% (n=181 out of 301) 
proteins identified in the first cohort also identified in the second. These proteins were 
explored in greater depth by pathway analysis.  
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Figure 17: Hierarchical clustering of sera protein expression in dcSSc patients 
 
237 analytes analyzed by unsupervised clustering that were identified again as 
differentially regulated in dcSSc patients (n=20) compared to healthy controls (n=11), as 
well as correlated with MRSS (FDR<0.02). Here, red and blue indicate high or low 
expression; Group 1 indicates healthy controls and Group 2, with the exception of one 
healthy control, indicates dcSSc patients. 
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Pathway Analysis 
In order to examine the biological pathways implicated by the proteins discovered to be 
regulated using the combined data from these two cohorts, we used integrated pathway 
analysis to predict upstream mediators and transcriptional regulators underlying the 
phenotypic differences between SSc and healthy patients. Upstream regulators identified 
by IPA highlighted several cytokines:  TNF, TFGB, IFNG, and IL-13 (Table 14). Several 
proteins known to be regulated by TGFB appeared to drive this pathway: periostin, 
ADAM12, CTGF, tenascin and Timp1 involved in the underlying TGFβ signature in the 
serum of dcSSc patients (Figure 18). The pathway analysis also predicted receptor and 
transcriptional upstream regulators, though IPA software does not take into account 
regulation direction for computation of p-values. IPA also predicted several upstream 
receptors (TLR3 and IL6ST) and transcriptional regulators (p53, FOXO3, TICAM1, 
SMAD4, and SMAD3) to be activated based on literature-derived data for which 
directional regulation was taken into account. (Table 15)  
 
 
 
Table 14.  Top Upstream Regulators in Sera of dcSSc Patients  
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Figure 18: TGFb Pathway Signature in Sera of dcSSc patients  
Graphical representation of the proteins involved the TGFb signature pathway of dcSSc 
patients. Colors indicate predicted activation (orange: activated, and blue: inhibited) and 
regulation status (Red upregulated, Green downregulated) of molecules in the dataset. 
Lines between molecules depict predicted relationships based on what is known in the 
current literature.  
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Table 15.  Upstream regulators Predicted to be Activated or Inhibited 
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Cross-sectional putative biomarker validation 
We selected 10 proteins from the Somascan proteins, based on choosing proteins in 
different clusters, a subjective assessment of potential biological relevance, and previous 
literature to be tested for validation in a separate, larger cohort (thirty one SSc patients, 
and twelve healthy controls; patient characteristics in Table 13). Eight out of the ten 
proteins tested successfully validated (CXCL11, sTNF-R1, SPON1, FSTL3, ST2, 
Endostatin, IGFBP-2, and CXCL13) as different from healthy controls (p<0.03) and 
retained moderate cross-sectional correlations with the MRSS (Spearman’s rho>0.3, 
Table 16). Two proteins did not validate as different in SSc patients compared to healthy 
controls (Afamin, and sE-Selectin). Three of the analytes, identified as different from 
healthy control and correlating with MRSS, have not previously been highlighted in SSc 
literature: IGFBP-2, FSTL3 and SPON1. ELISA data from these three proteins are 
depicted in detail along with ST2, which had the strongest cross-sectional correlation 
with MRSS (Figure 19).  
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Analyte  Difference From HC 
Correlation with 
MRSS 
 sE-Selectin 0.26 -0.4 
Afamin  0.23 -0.11 
IGFBP2 0.03 0.32 
I-TAC 0.03 0.31 
FSTL3 0.03 0.37 
BLC 0.01 0.35 
IL1 R4 0.01 0.45 
sTNF R1 0.003 0.34 
Spondin-1 0.006 0.25 
Endostatin 0.002 0.34 
  
Table 16. Summary of cross-sectional ELISAs 
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Figure 19: Validation of cross-sectional biomarkers 
Graphs show differences Insulin-like-growth factor 2 (IGFBP-2), Follistatin-like 3 
(FSTL3), Spondin-1, and IL-1R4 (ST2) protein concentrations. Top panel shows 
statistical significance of protein concentration difference (Wilcoxon signed rank test) 
from healthy control of IGFBP-2, FSTL3, Spondin-1, and IL-1R4. Bottom panel shows 
the relationship (Spearman’s rho) between protein concentrations and the MRSS.   
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Altered expression in SSc skin biopsies, and PBMCs  
These four analytes (IGFBP-2, FSTL3, SPON1, and ST2) were further examined at the 
mRNA level in both SSc skin and PBMCs (Patient Characteristics in Table 17). Figure 
20A demonstrates the up-regulation of gene expression in the skin of patients with 
diffuse SSc (n=9) compared to healthy control (n=4) with a three fold increase for 
IGFBP-2 (p=0.003), and FSTL3 (p=0.006), and a trend for a significant two fold increase 
in both SPON1  (p=0.06) and ST2 (p=0.15).  
In order to determine if increased expression of any of these analytes was derived 
from an immunological component of the blood cells SSc PBMCs were examined at the 
mRNA level. Figure 20B demonstrates the significant up-regulation of gene expression in 
PBMCs from patients with SSc (n=7) and healthy controls (n=8) with a 3.7 fold increase 
in FSTL3 (p=0.004), a trend towards a significant 4-fold increase in IGFBP-2 (p=0.07), 
and no significant increase in SPON1  (p=0.46) or ST2 (p=0.32) by qPCR.  
  
		
107 
 
Table 17. Patient Characteristics for mRNA Skin Biopsies and PMBCs   
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Figure 20: Altered mRNA expression in SSc skin biopsies, and PBMCs 
Graphs show differences (Wilcoxon signed rank test) of Insulin-like-growth factor 2 
(IGFBP-2), Follistatin-like 3 (FSTL3), Spondin-1, and IL-1R4 (ST2) gene expression as 
compared to healthy controls in both skin biopsies (top panel) as well as peripheral blood 
mononuclear cells (PBMCs: bottom panel). 
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Evaluating and modeling longitudinal change  
The eight analytes that successfully validated cross-sectionally (CXCL11, sTNF-R1, 
SPON1, FSTL3, ST2, Endostatin, IGFBP-2, and CXCL13) were examined for 
longitudinal change, in diffuse SSc patients (n=17), with sequential visits where both a 
serum sample was collected and MRSS was recorded. As part of the sample selection 
criteria the same doctor conducted the skin score at both of the visits, and patient 
characteristics are described in Table 18, Figure 21 illustrates change in each individual’s 
MRSS and analyte level, but does not depict time. Mixed models were used to describe 
the longitudinal data in order to account for all intrinsic within-patient correlations 
between the different analyte concentrations and MRSS, beta-coefficients, standard errors 
of beta-coefficients, and p-values for these models are included in Table 19. Variables 
were selected for a multi-analyte model by penalized regression (LASSO) and the 
combination of two analytes (ST2 and SPON1) was used in a mixed model to best 
describe longitudinal change (Figure 22).  
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Table 18. Baseline Patient Characteristics for Longitudinal Studies 
  
		
111 
 
Figure 21: Longitudinal change in analyte levels  
Graphs show the patterns of longitudinally protein concentrations and change in 
MRSS. Each color represents an individual patient followed over multiple visits. 
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Figure 22: Variable Selection   
Graph shows the beta coefficient estimates of protein analyte concentrations for 
mixed model analysis  
  
		
113 
 
Table 19. Beta Coefficient Estimates  
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Validating model of longitudinal change 
The final equation used to describe a biomarker score was 17.65+3.42*(SPON1 
concentration)+4.379*(ST2 concentration). The biomarker score from this combination 
of SPON1 and ST2 correlated well (Pearson’s r=0.58) with observed MRSS in a 
discovery cohort (Figure 23). The beta-coefficients were held constant from the discovery 
cohort and the model of longitudinal change was than tested and successfully validated in 
two independent cohorts collected at the University of Pittsburgh and the Hospital of 
Special Surgery (Pearson’s r=0.33 and r=0.44, respectively), and a third cohort from 
Boston University (Pearson’s r=0.42, Figure 23), patient characteristics for validation 
cohorts are described in Table 18. Both ST2 and Spondin-1 were tested by ELISA on the 
sera from Group 2 of the anti-TGFβ trial of Fresolimumab. There was no significant 
decrease in the biomarker with treatment, due to a consistent increase of ST2, there was 
however a significant decrease of Spondin-1 that corresponded with treatment. (Figure 
24) 
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Figure 23: Testing and validation of the proteomic biomarker  
Graphs show correlations between biomarker score derived using a mixed model 
equation. Values used to develop the model and in the third validation cohort are from 
Boston Medical Center patients. Values used to validate the model (cohort one and two) 
are from outside R-values and corresponding p-values are indicated on each panel. 
Dotted line indicates 95% confidence intervals of the regression line.  
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Figure 24: The proteomic biomarker in Fresolimumab 
Graphs show change in levels of biomarker score derived using a mixed model 
equation. Paired non-parametric Wilcox signed rank test p-values are indicated. Dotted 
line indicates no change from baseline.  
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Discussion: 
This method of investigation into the proteome allowed for the identification of 
multiple putative biomarkers. Our results show 181 circulating serum proteins associated 
with dSSc disease that correlated with the MRSS cross-sectionally in two independent 
cohorts. We validated a subset of 8/10 biomarkers of the 181 biomarkers identified by 
Somascan in the serum of SSc patients as different from healthy control and cross-
sectionally correlated with MRSS. We developed a robust longitudinal biomarker for the 
MRSS using ELISAs that could thus be applied as an outcome measure in future clinical 
trials. We show, alternatively, that the SOMAscan platform provides a combination of 
analytes that correlate strongly with the MRSS. Although we have validated this cross-
sectionally it has not yet been validated as a longitudinal biomarker. Several of the 
proteins that were increased in the serum were also found increased at the mRNA level in 
skin biopsies (FSTL3, IGFBP-2, SPON1). These observed increases at the mRNA level 
consistent with previously published microarray studies by both our group (132) as well 
as independent microarray studies.(144). Thus, as might be expected, cells in dermal 
tissues likely secrete many or most of these circulating proteins.    
Notably, FSTL3 was also upregulated at the mRNA level in PBMCs. We have 
previously reported altered IFN-regulated gene expression by PBMCs (145). However 
FSTL3 does not cluster with these IFN-regulated genes (Lafyatis unpublished 
observations). Instead in fibroblast it is regulated by TGFβ, suggesting it may be 
regulated by TGFβ in leukocytes. This suggests that the upregulation of lymphocytes and 
monocytes in the circulation could be due in part to TGFβ.  
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We identified and validated two markers that reflected longitudinal change in 
MRSS, SPON1 and IL1-R4. Our data demonstrate that IL4-R1/ST2 is increased in the 
circulation and skin of SSc patients. ST2/IL1-R4, as the receptor for IL-33, enhances 
classic TH2 cell responses in a broad spectrum of diseases (146), an may also activate  
TH2 activation in SSc  (147). The IL33/ST2 system has previously been implicated in 
SSc and is overexpressed in early disease (148). Recently, IL1-R4/ST2 was found on SSc 
skin-localized Treg cells (149) as well as upregulated in several SSc organs (skin, lung, 
kidney, heart, esophagus) (148). This is consistent with our data showing ST2 increased 
in SSc skin and with recent literature that implicates ST2 in tissue specific immune 
regulation (150). In contrast, soluble ST2 is increased in the sera in several chronic 
inflammatory diseases, such as asthma, where in airway inflammation it was found to 
have antagonistic effects on IL-33 signaling (151). The precise role in SSc will thus 
require further study, but it is likely a mechanistically meaningful biomarker.  
SPON1 has not been previously described in the SSc literature, it has however 
been shown to be increased in other rheumatic diseases including in the cartilage of 
osteoarthritis (OA) patients (152). In several studies SPON1 has been linked to activation 
of latent TGFβ (152, 153). This link with TGFβ is consistent with our observations here; 
TGFβ did not directly induce SPON1 however in patients treated with anti-TGFβ (154) 
SPON1 decreased significantly after treatment. This observed decrease in SPON1 along 
with the longitudinal correlation with MRSS, suggests that SPON1 might reflect TGFβ 
driven fibrotic aspects of disease pathogenesis.  
A large fraction of serum proteins, representing almost 16% of the serum proteins 
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assayed, showed altered levels in dcSSc patients. This dataset allowed a unique 
opportunity to examine potential upstream regulators of these serum proteins. In addition 
to TGFβ, the protein patterns pointed to upstream regulation by TNF, IFNg, IL-13 in the 
sera suggest a widespread pattern of inflammation and immune activation, including 
innate immune (TNFa), TH1 (IFNg) and TH2 (IL-13 responses). The predicted activation 
of FOXO3 is intriguing, as it has previously been suggested that SSc serum induced 
endothelial progenitor cell apoptosis is mediated by the Akt-FOXO3a-Bim pathway 
(155). The predicted activation of TICAM and TLR3 in conjunction with the 
unsupervised heatmap cluster of the chemokines consisting of CXCL13, CXCL11, 
CXCL10, CCL19, and CCL2 is striking as it includes multiple proteins we have 
described previously in SSc (111, 156). Several of these proteins point to innate 
immune/type I interferon activation in the serum of dcSSc patients (CXCL10 and 
CXCL11), while others more to TH2 activation (CCL2) and vascular inflammation 
(CCL19). These and other pathway indications of innate immune activation, including 
IL6, IL1b, TLR3, TICAM, support previous work showing chronic stimulation of TLR3 
can induce fibrosis dependent at least in part through TICAM1.(157) 
The upstream regulation by TGFβ, and predicted activation of the SMADs and 
p53 is particularly interesting. The first work identifying p53 as a gene specific partner 
for the SMADs was done in early development studies. (158, 159)  In particular SMAD 
2/3 were found to directly bind to p53 in a TGFβ dependent fashion. (158) The genes 
controlled by this co-regulation have been linked to extracellular matrix functions. (160) 
This link between p53 and TGFβ is supported by the pathway analysis in the SSc sera 
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with both SMAD2 and p53 predicted to be activated corresponding with a strong TGFβ 
signature. Additionally, since previous studies have shown that experimental 
administration of a p53 inhibitor (pifithrin-α) attenuates fibrosis (161) this data highlights 
a potential therapeutic opportunity in SSc.  
In fact the similarity of these protein patterns across diffuse patients is quite 
striking. However, unlike the gene expression studies, there are no apparent subsets of 
dcSSc patients (22). This could be in part due to the clinical similarities of these patients; 
all being early diffuse with relatively high skin scores (mean MRSS=30). Alternatively 
the consistency of the regulated proteins in dcSSc patients could be due in part to both 
accentuating the variability that may come with collecting a skin biopsy. In contrast 
circulating sera is coming in contact with surrounding tissues all over the body, 
potentially giving a more accurate picture of the total systemic disease.  
There are limitations to this data and biomarker based on selection criteria of both 
the patients as well as the selection of the proteins of interest. These patients were not 
chosen based on lung complications, and serial changes in other clinical measures such as 
forced vital capacity, or digital ulcers were not examined. These clinical measures might 
have influenced levels of the serum proteins independent of the degree of skin disease.  
The proteins chosen from the high throughput analysis to be focused on here were parsed 
based on combined measures of differential regulation and correlation with MRSS. Using 
this method of selection could have intrinsically excluded some proteins that were highly 
correlative with MRSS and not differentially regulated, and vice versa. Despite these 
limitations, we have identified a pharmacodynamic biomarker that can provide objective 
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supplementary information to the MRSS and other clinical measures during the course of 
a clinical trial. 
Materials & Methods: 
Patients 
Institutional Review Boards, at Boston University, University of Pittsburgh and the 
Hospital for Special Surgery, approved the collection of all sera samples and clinical data 
for the discovery and validation cohorts. Serum from patients was collected into a serum 
separator tube, allowed to clot, aliquoted and stored at -80oC.  
Somalogic Analyses 
Sera proteins were analyzed by SOMAcan (SomaLogic Boulder, CO, USA). Protein data 
was analyzed for correlation with MRSS (Spearman’s), and difference from healthy 
controls (Wilcoxon signed rank test). Analytes for further study were selected based on 
the combined p-values from these two analyses by Fisher’s method (FDR<0.02).  These 
parsed analytes (n=43 and n=237 analytes out of 1129) were clustered and visualized 
using the R environment for statistical computing (version 3.2.1). The clustering was 
unsupervised and used Spearman’s correlation and complete linkage. Identification of 
pathways linked to the differentially expressed proteins was performed using QIAGEN’s 
Ingenuity Pathway Analysis (IPA, QIAGEN Redwood City, CA, USA).   
ELISA Validations 
Concentrations of candidate proteins were measured using commercial ELISA kits from 
R&D Systems (Minneapolis, MN, USA) for soluble E-Selectin (sE-Selectin; DSLE00: 
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150uL serum), Endostatin (DNST0: 10uL serum), Interleukin-1 receptor 4 (ST2; 
DST200: 10uL serum), C-X-C motif chemokine 11 (CXCL11;DCX110: 100uL serum), 
C-X-C motif chemokine 13 (CXCL13;DCX130: 100uL serum), soluble tumor necrosis 
factor receptor 1 (sTNF-R1: DRT100: 25uL serum), Insulin-like growth factor-binding 
protein 2 (IGFBP-2; DGB200: 5uL serum), and Follistatin-related protein 3 (FSTL3; 
DFLRG0: 50uL serum); or from US Biologics for Afamin  (AFM; 023191: 5uL serum) 
and Spondin-1 (SPON1;028164: 50uL serum).  
Statistical Analysis 
Wilcoxon signed rank test was used to test the difference in SSc analyte concentrations 
from healthy controls. Spearman correlations were used for cross-sectional correlations 
between analyte concentrations and MRSS. Mixed models were employed in the 
longitudinal data to account for the intrinsic within-patient correlations between analyte 
concentrations and MRSS. Variables were selected for a multi-analyte model by 
penalized regression (LASSO).(162, 163) Since predictor variables were on widely 
different scales, ELISA data was normalized (log2), centered and scaled (z-scored) to 
build a multi-analyte mixed model. In order to validate this model in independent datasets 
the beta-coefficients derived from the discovery cohort were held constant for ELISA 
data of the validation datasets. The correlation (Spearman’s) between the change in 
model score and the change in MRSS was used to assess model validity.  
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RNA isolation 
Skin biopsies (3mm) were performed on the mid-forearm and placed in RNAlater. The 
skin was minced and homogenized with a Polytron homogenizer (Capitol Scientific, 
Austin, TX, USA). Peripheral blood mononuclear cells (PBMCs) were collected in 
vacutainer CPT tubes (Becton Dickinson), processed within 30 minutes after collection, 
and lysed in RNeasy RLT buffer (Qiagen).  RNA from biopsies as well as PBMCs was 
purified using the RNeasy Mini Kit (Qiagen), and the concentration of total RNA 
measured (Nanodrop 1000; ThermoScientific).  In accordance with the protocol for 
SuperScript II reverse transcriptase (Invitrogen) 200ng of RNA was then used to 
synthesize cDNA with random primers.  cDNAs were then used as templates for qPCR 
with Taqman (Applied Biosystems) gene expression assays using the following primer 
pairs: 18S (4310893E); FSTL3 (Hs00610505_m1); SPON1 (Hs01120488_m1); IGFBP-2 
(Hs01040719_m1); and ST2 (Hs00249384_m1).  
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CHAPTER SIX: A SERUM BASED PROTEOMIC CLASSIFIER FOR THE 
SCREENING AND DIAGNOSTIC EVALUATION OF PULMONARY 
ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS  
Abstract: 
Rationale: Systemic sclerosis associated pulmonary arterial hypertension (SSc-PAH) is a  
leading cause of death in SSc. Identification of a serum based proteomic diagnostic 
biomarker for SSc-PAH would allow for rapid non-invasive screening and could 
positively impact patient survival. Objectives: To identify and validate novel proteins 
that could potentially facilitate the classification of SSc-PAH 
Methods: All SSc-PAH patients were diagnosed by right heart catheterization (RHC). 
13-treatment naïve SSc-PAH patients had serum collected at time of diagnostic RHC and 
were used as the discovery cohort for the protein-expression classifier. Two specific 
proteins, Midkine and Follistatin-like 3 (FSTL3) were than validated by enzyme linked 
immunosorbent assays. Midkine and FSTL3 were used in combination to classify SSc-
PAH and were tested for validation in two separate cohorts (n=24, n=10).  
Measurements and Main Results: In the discovery cohort the classifier had an area 
under the receiver-operating-characteristic curve (AUC) of 0.94 (95% confidence interval 
(CI), 75 to 95), a sensitivity of 99%, and a specificity of 94%. In the first validation 
cohort the classifier had an AUC of 85% (95% CI, 67 to 94), a sensitivity of 77%, and a 
specificity of 75%. In the second validation cohort the classifier had an AUC of 92% 
(95% CI, 77 to 95), a sensitivity of 91%, and a specificity of 83%. Conclusions: These 
findings indicate that there is a clear delineation between overall protein expression in 
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sera from SSc patients and those with SSc-PAH. Furthermore the combination of 
Midkine and FSTL3 can serve as an SSc-PAH biomarker.  
Introduction: 
Direct lung involvement is the most common cause of death in Systemic sclerosis 
(SSc) patients, with 12% of SSc patients affected by SSc-associated pulmonary arterial 
hypertension (SSc-PAH) and those patients have an estimated 50% 3-year survival 
rate(164). Early and accurate diagnosis of pulmonary arterial hypertension (PAH) is 
clinically challenging. SSc-PAH diagnosis currently relies on right heart catheterization 
(RHC), an invasive procedure, not suitable for screening, that is typically only performed 
in patients with a high index of suspicion based on echocardiogram and other weakly 
correlative criteria(20, 165).   
Since the response to PAH-specific therapeutics is substantially worse in patients 
with advanced pulmonary vascular disease, earlier diagnoses and faster treatment is 
associated with better outcomes for patients(21, 166). Identification of a diagnostic 
biomarker that would allow for rapid non-invasive screening could positively impact 
patient survival, supplement current screening methods, and reduce the need for 
diagnostic RHC.  
Currently the most widely accepted existing screening tool for the diagnosis of 
SSc-PAH is echocardiographic assessment of systolic PAP (sPAP), as it has shown good 
correlation (r=0.83) with the diagnosis of PAH by RHC(167). However there have been 
several subsequent studies that highlight both the value and limitations of detection by 
echocardiogram including a 45% false positive rate (168-170).  
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Echocardiogram has been also been studied in combination with other measures. 
The most studied and only clinically available additional PAH biomarkers are markers of 
heart strain/failure such as brain natriuretic peptide (BNP) and N-terminal fragment of 
pro-BNP (NT-proBNP), which have similar diagnostic accuracy(44). Natriuretic peptides 
are integral to cardiovascular homeostasis and circulating levels of have been shown to 
correlate with hemodynamic measurements, predict disease prognosis and mortality(45). 
These tests have shown to be generally specific for SSc-PAH, but lack sensitivity(46). 
Other groups have studied potential new biomarkers for diagnosing PAH and some have 
shown in preliminary studies to be superior to both BNP and NT-proBNP(49-51). 
However these findings are restricted to single studies and have yet to be validated.  
The clinical use of gene expression for the classification of different biological 
disease states is well established(171).  We have previously described SSc-PAH 
associated gene-expression patterns that highlight IFN-regulation and 
monocyte/macrophage activation in disease pathogenesis in peripheral blood 
mononuclear cells (PBMCs)(53, 172).  mRNA expression studies from PBMCs showed 
specific SSc-PAH patterns associated with PAH. Thus, we hypothesized that wide scale 
proteomic studies of serum might also allow for a diagnostic biomarker of SSc-PAH. 
This hypothesis was further supported by our previous small proteomic study, in which 
we identified 17 cytokines associated with SSc-PAH that were markers of vascular injury 
and inflammatory response (53).   
 In this study we utilized a much more robust proteomic technology and to identify 
and novel proteins that could facilitate the diagnosis of SSc-PAH.  We show that in 
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combination FSTL3 and Midkine are highly diagnostic for SSc-PAH, indicating that 
current serum assays of PAH could be dramatically improved with these additional serum 
biomarkers, and thus avoid many right heart catheterizations.  
Methods: 
Patient Selection 
Diagnosis of PAH is defined by hemodynamic pressures measured by RHC and 
requires an elevated mean pulmonary artery pressure (mPAP) of >25mmHg, a pulmonary 
capillary wedge pressure of <15mmHg, and a pulmonary vascular resistance of >3 Wood 
units(173).  Out of all the patients meeting the diagnostic criteria for SSc-PAH those 
(n=13) sent to somalogic had limited skin disease (limited cutaneous systemic sclerosis: 
lcSSc) and were PAH treatment naïve with sera collected at time of diagnostic RHC.  
Somalogic Analyses 
Sera proteins were analyzed by SOMAcan (SomaLogic Boulder, CO, USA). 
Protein data was analyzed for difference from SSc-PAH (Wilcoxon signed rank test). 
Analytes for further study were selected based on the p-values (FDR<0.05).  These 
parsed analytes were clustered and visualized using the R environment for statistical 
computing (version 3.2.1). The clustering was unsupervised and used Spearman’s 
correlation and average linkage. Identification of pathways linked to the differentially 
expressed proteins was performed using QIAGEN’s Ingenuity Pathway Analysis (IPA, 
QIAGEN Redwood City, CA, USA).   
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ELISA Validations 
Concentrations of candidate proteins were measured using commercial ELISA 
kits from R&D Systems (Minneapolis, MN, USA) for Follistatin-related protein 3 
(FSTL3; DFLRG0: 50uL serum); or from Abcam (Cambridge, MA, USA) for Midkine  
(MDK; ab193761: 200uL serum).  
Statistical Analysis 
Wilcoxon signed rank test was used to test the difference in SSc analyte 
concentrations from SSc-PAH. Models of discreet variables were developed using 
logistic regression and multiple logistic regression. Sensitivity and specificity of discrete 
variables were assessed using receiver-operator characteristic (ROC) curves, plotting the 
sensitivity on the y-axis and 1-specificity on the x-axis. The area under the curve (AUC) 
of a ROC was computed to provide a global measure of performance and for comparing 
biomarker performance, with AUC of .90-1 considered excellent, .80-.90 considered 
good, 0.7-0.8 considered fair, 0.6-0.7 considered poor, 0.5-.06 considered without value. 
Various methods can be applied to choose the best threshold level of the biomarker to 
maximize sensitivity and specificity.  
RNA isolation 
cDNAs were then used as templates for qPCR with Taqman (Applied 
Biosystems) gene expression assays using the following primer pairs: 18S (4310893E); 
FSTL3 (Hs00610505_m1); MDK (Hs00171064_m1).  
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Results: 
Pathway Analysis of protein expression 
Somascan protein expression was evaluated in sera from thirteen subjects with 
Systemic sclerosis associated pulmonary arterial hypertension (SSc-PAH) and sixteen 
subjects with limited systemic sclerosis (lcSSc) (Table 20).  
 
Table 20: Baseline Demographics of SSc-PAH patients   
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Sixty-four proteins were identified as both differentially regulated in SSc-PAH 
patients compared to lcSSc controls (False Discovery Rate q≤0.05). Analytes meeting 
these criteria were analyzed by unsupervised clustering for both proteins and subjects.  
SSc-PAH and lcSSc controls clustered independently (Figure 25).  The proteins that were 
used to classify the difference between SSc-PAH and lcSSc controls were explored in 
greater depth by pathway analysis.  
There was a cluster of chemokine signaling molecules activated including, 
CCL19, CXCL13, CXCL11, CCL28, and CCL21. As well as several TGFB related 
molecules including FSTL3 and Spondin-1. Using IPA several activated upstream 
regulators were identified within the data including a strong Interferon Gamma signature 
(Figure 26). 
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Figure 25: Differential regulation of sera protein expression in SSc-PAH patients  
Unsupervised hierarchal clustering of SSc-PAH patients (green color bar) and SSc 
patients with no lung disease (yellow color bar). Here, red and blue indicate high or low 
expression   
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Figure 26: INFg Pathway Signature in Sera of SSc-PAH patients  
Graphical representation of the proteins involved the activated INFg signature pathway of 
SSc-PAH patients. Colors indicate predicted activation (orange: activated, and blue: 
inhibited) and regulation status (Red upregulated, Green downregulated) of molecules in 
the dataset. Lines between molecules depict predicted relationships based on what is 
known in the current literature.  
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Putative biomarker selection 
 Five of these proteins (Follistatin-related protein 3: FSTL3, Spondin-1, junctional 
adhesion molecule C: JAM-C, CCL28 and Midkine) were selected to be examined for 
their individual ability to discriminate between subjects with PAH and those without in 
silico (logistic regression) based on biological relevance, unsupervised clustering 
methods and fold change>2 (Figure 25). Looking at specific proteins FSTL3 and Midkine 
had nearly equal area under the curve (Figure 27: AUC: 0.90 and 0.89). However, it was 
observed that FSTL3 performed better than Midkine where high sensitivity was required, 
and Midkine performed better than FSTL3 when high specificity was required. 
Additionally Midkine and FSTL3 were found not to correlate with each other. These 
proteins were then looked at in combination using a generalized linear model.  
Using a multiple logistic regression model for FSTL3 and Midkine in 
combination for every one-unit increase in the RFU of FSTL3 and Midkine the log odds 
of PAH (vs no PAH) increases by 0.50 for FSTL3, with a confidence interval of (0.18, 
0.81) and 0.12 for Midkine, with a confidence interval of (0.05, 0.19). Based on these 
observation FSTL3 and Midikine seemed to have the highest potential to identify PAH in 
SSc patients and were the two proteins of the highest priority to evaluate in other SSc 
patients in order to validate their diagnostic ability to discriminate between SSc subjects 
with and without PAH.  
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Figure 27: Receiver operator characteristic curves of SOMAlogic data 
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Putative biomarker validation 
 The ability to discriminate between SSc subjects with and without PAH using 
Midkine and FSTL3 was confirmed by enzyme-linked immunosorbent assay (ELISA) on 
the patients with remaining sample. Both proteins were confirmed to be elevated in 
subjects with SSc-PAH compared to those without PAH, and when modeled together 
using multiple logistic regression they showed an increase in discriminatory power.  
 Serum from two validation cohorts was then used to test the discrimination of 
Midkine and FSTL3. Clinical characteristics in the validation cohorts were similar but 
not identical to the test cohort (Table 20). Not all samples were collected day of RHC; 
due to this some patients were already under treatment for PAH. Additionally some of the 
patients also had other pulmonary complications such as interstitial lung disease (ILD).  
 Both cohorts showed that there is a consistent and significant increase (p<0.01) in 
both FSTL3 and Midkine protein concentration that is associated with SSc-PAH (Figure 
28). Logistic and multiple logistic models were created based on protein concentrations 
(Figure 29). In the discovery cohort the classifier had an area under the receiver-
operating-characteristic curve (AUC) of 0.94 (95% confidence interval (CI), 75 to 95), a 
sensitivity of 99%, and a specificity of 94%. In the first validation cohort the classifier 
had an AUC of 85% (95% CI, 67 to 94), a sensitivity of 77%, and a specificity of 75%. In 
the second validation cohort the classifier had an AUC of 92% (95% CI, 77 to 95), a 
sensitivity of 91%, and a specificity of 83%.  
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Figure 28: ELISA validation cohort data 
Graphs show differences (Wilcoxon signed rank test) of SSc-PAH Follistatin-like 3 
(FSTL3), and Midkine protein concentrations as compared to SSc patients with no lung 
disease in the test cohort (A) as well as two independent validation cohorts (B&C). 
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Figure 29: Receiver operator characteristic curves of ELISA data 
Graphs show differences Receiver operator characteristic curves of SSc-PAH Follistatin-
like 3 (FSTL3), and Midkine protein concentrations as well as the two in combination as 
compared to SSc patients with no lung disease in the test cohort (A) as well as two 
independent validation cohorts (B&C). 
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Conclusions:  
This method of investigation into the circulating proteome of SSc-PAH allowed 
for the identification of multiple putative biomarkers. Our results show 64 circulating 
serum proteins that are associated with SSc-PAH compared to lcSSc, thus successfully 
identifying a serum proteomic classifier for the diagnostic evaluation of SSc-PAH. In 
particular we showed that the combination FSTL3 and Midkine are highly diagnostic for 
SSc-PAH. 
FSTL3 and Midkine are altered in heart failure. (174, 175) FTSL3, a TGFb 
regulated protein, has been shown to inhibit the protective actions of activin A on cardiac 
myocytes.  
A fraction of the serum proteins assayed showed altered levels in SSc-PAH 
patients, and this dataset allowed us a unique opportunity to examine potential upstream 
regulators of these proteins. In addition to INFg the sera suggest a widespread pattern of 
chemokine activation. Of particular note was the activation of CCL19, CXCL13, and 
CCL21, which are implicated, in tertiary lymphoid structure (176).  
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CHAPTER SEVEN: CONCLUDING REMARKS 
Summary of Results 
Biomarkers  
 
The use of gene expression for the discovery of biomarkers and classification of 
different biological and disease states is well established. There are countless manuscripts 
extolling the differences in gene and protein expression patterns in all types of tissues. 
Biomarkers in general not only permeate the clinical care setting as routine laboratory 
test but also have invaded the home health care setting with self-administered pregnancy 
tests (diagnostic biomarker of hCG).  
Biomarkers can provide valuable information for both clinical and translational 
science. As discussed above, many genes and proteins have been shown to be different 
between patients with Systemic sclerosis (SSc) and healthy persons and between subsets 
of patients with SSc, but the clinical utility of such markers has been difficult to establish.  
Skin Biomarkers in Systemic Sclerosis 
Clinically relevant biomarkers such as those described here could be used to 
design more efficient clinical trials while simultaneously creating a bridge to 
understanding disease pathogenesis. Biomarkers are valuable in clinical settings where a 
disease such as SSc has manifestations that are difficult to measure objectively. 
Generally, strong correlations between biomarkers and clinical measures of disease 
activity suggest direct roles in the disease process; the more robust the correlation the 
more likely a biomarker is implicated in pathogenesis.  One of the main goals of the 
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studies presented here was to identify a pharmacodynamic biomarker that could be 
effectively implemented into clinical trials to provide supplementary and more objective 
and therefore likely more reproducible information to the modified Rodnan skin score 
(MRSS) regarding drug efficacy.  
We were able to identify a robust biomarker of SSc skin disease based on gene 
expression in the skin. Changes in mRNA correlated with changes in the clinical measure 
of disease activity, the MRSS. THBS1, based on the consistent observation of its high 
correlation with the MRSS across multiple datasets is the single most reliable 
pharmacodynamic biomarker of skin disease in SSc. We also defined and validated a 2-
gene pharmacodynamic biomarker (2GSSc) of SSc skin disease based on mathematical 
considerations that we showed correlated strongly with the MRSS both cross-sectionally 
and longitudinally. We standardized the measurement of expression of the genes making 
up this pharmacodynamic biomarker using the nanostring platform. This biomarker was 
then validated in several clinical trials, where it was sensitive to change and differed 
among therapeutics.  
Biomarkers can also be used at the interface between clinical and translational 
medicine. Exploring the effects of drug treatment on biomarkers can lead to insights into 
the roles of drug-targeted pathways in pathogenesis. The data presented here highlight the 
intrinsic link between the 2GSSc biomarker and the role of drug-targeted pathways in 
disease pathogenesis. TGFβ is known to regulate THBS1 mRNA expression in vitro and 
we show here in two separate studies how it clusters consistently and tightly with other 
TGFβ-regulated genes. TGFβ activation and its effect on dermal cells has long been 
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implicated in the pathogenesis of SSc and is speculated to represent a step directly in the 
pathway leading to fibrosis and resulting in clinical manifestations such as increasing 
MRSS. This link to pathogenesis is key for performance of THBS1 as a 
pharmacodynamic biomarker, since biomarkers that are not directly part of the 
pathogenic pathway might be equally affected by ineffective therapeutic interventions.  
MS4A4A is a macrophage marker that is the other half of the 2GSSc biomarker. 
MS4A4A is closely related structurally to CD20 seen on B cells, and CD20 is currently 
targeted by the anti-CD20 therapeutic, Rituximab. MS4A4A was shown here to cluster 
with other macrophage markers. Furthermore, patients treated with fresolimumab (anti-
TGFβ) showed a trend to decrease levels of the macrophage/monocyte-associated genes, 
CD163 and MS4A4A. A change in the macrophage marker genes in the fresolimumab 
trail is not as dramatic as the TGFβ-regulated genes, but since there was a decrease it may 
be suggesting that inhibition of TGFβ can contribute in resolving the perivascular 
inflammation in SSc (87).  
Our work looking at local forearm scores and corresponding gene expression 
elucidated that the effect of TGFβ on THBS1 most likely represents a step relatively 
distal in the pathogenic process. We showed that TGFβ regulated genes (THBS1, COMP) 
correlated most highly with the skin score at the biopsy site as opposed to the total body 
MRSS. These TGFβ associated genes may represent molecular events closest to local 
clinical manifestations, whereas expression of other genes that correlate more closely 
with the MRSS than local forearm skin score may reflect more generalized immune 
dysfunction that is driving pathogenesis. Alternatively, altered macrophage gene 
		
142 
expression that does not correlate cross-sectionally with the skin score (although it does 
correlate longitudinally with MRSS in the 2GSSc biomarker) may represent molecular 
events earlier in the pathogenic cascade. This is consistent with earlier work suggesting 
that CD14 is a prognostic biomarker for SSc(125).  
Detecting events both early as well as distal in pathogenesis is also important for 
designing pharmacodynamic biomarkers, as effective therapeutics targeting pathogenic 
events downstream from the biomarker will remain undetected by the biomarker.    
Multiple pharacodynamic biomarkers might be used tailored to specific drugs with 
known molecular mechanisms.  
Serum Biomarkers in Diffuse Cutaneous Systemic Sclerosis 
Although skin mRNA gene expression is likely to provide the best biomarkers for 
skin disease, it is invasive and not practical to assess longitudinally. Here we also 
identified serum protein biomarkers of SSc disease. Using Somascan technology we 
investigated large-scale changes in the proteome. The protein patterns we describe here 
point to upstream regulation by TNF, IFNg, and IL-13 in the sera, which suggest a 
widespread pattern of inflammation and immune activation 
We found perhaps, unsurprisingly, a similarity between patterns of alterations in 
the proteome to previously described gene expression studies describing different subsets 
of patients are quite striking. The patterns between patients are also relatively conserved 
which suggests that using serum, which comes in contact with more organs than the skin 
biopsies alone, perhaps giving a more systemic picture of the total disease state.     
Starting with correlations between clinical disease states and protein 
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concentrations we used a linear mixed model analysis to identify two serum proteins that 
correlate highly with longitudinal changes in the MRSS. We then validated these findings 
through several independently collected cohorts. 
The two markers that reflected longitudinal change in MRSS were SPON1 and 
IL1-R4. Previous to this study IL4-R1/ST2 had been reported as increased in the 
circulation and skin of SSc patients. The finding that IL1-R1/ST2 correlate well with 
longitudinal change MRSS fit well with previous literature that implicates ST2 in tissue 
specific immune regulation (150). We also showed in our own pathway analysis of SSc 
sera presented here that there are widespread patterns of immune activation. Although the 
precise mechanistic role that this up regulation of ST2 has in SSc is still unknown and 
will require further study, it is likely to prove to be a mechanistically meaningful 
biomarker.  
The second marker, SPON1 that reflected longitudinal change in MRSS is new to 
the SSc literature. In several studies SPON1 has been linked to activation of latent TGFβ 
(152, 153). This link with TGFβ is consistent with our observations here, both in the 
pathway analysis and in the anti-TGFβ trial, fresolimumab (154) where the antibody to 
TGFβ significantly decreased SPON1 in patients. This observed decrease in SPON1, 
which corresponds to the observed decrease in MRSS, along with the longitudinal 
correlation with MRSS, suggests that SPON1 might be reflecting a more fibrotic aspect 
of disease pathogenesis.  
 Having a serum biomarker that combines both the fibrotic component of a disease 
(SPON1) as well as a marker of the immunological component (ST2) is more likely to 
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capture the pathways that drive pathogenesis. Also, as shown in the examination of the 
mRNA and local scores, the measures of the immunological component might be 
reflecting earlier disease, and the fibrotic component the later stages of disease. 
 
Serum Biomarkers in Pulmonary Arterial Hypertension Systemic Sclerosis 
The SOMAscan technology was used again to investigate the circulating 
proteome of SSc-PAH to identify multiple putative biomarkers. Our results show 64 
circulating serum proteins that are associated with SSc-PAH compared to lcSSc with no 
lung disease. Thus we successfully identified a serum proteomic classifier for the 
diagnostic evaluation of SSc-PAH. Within those 64 differentially regulated proteins there 
were a number of activated chemokines as compared to limited SSc with no lung disease. 
A strong activated pattern of Interferon Gamma indicating that many of the upregulated 
proteins are regulated by Interferon Gamma was evident in the circulating sera that 
supported previously published gene-expression patterns that highlighted IFN-regulation 
in peripheral blood mononuclear cells (PBMCs) of SSc-PAH(172).   
From these 64 differentially regulated proteins we showed that the particular 
combination FSTL3 and Midkine are highly diagnostic, in the independent cohorts, 
average sensitivity of 84% and an average specificity of 79% for SSc-PAH. These 
findings are plausible pathophysiologically since FSTL3 and Midkine are altered in heart 
failure. Additionally FSTL3 is regulated by TGFb and has a high affinity for Activin 
A(177). We also previously established that FSTL3 is elevated compared to healthy 
controls, in the sera, PBMCs, and skin of dcSSc patients. A role for the growth factor 
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Midkine has been implicated in the pathogenesis of hypertension, kidney diseases, and 
lung fibrosis (178-180) Midkine expression can be induced by oxidative stress and the 
activation of hypoxia-inducible factor 1-alpha (HIF-1a) (178).  
With the identification of these serum markers current serum assays of PAH could 
be dramatically improved with these additional serum biomarkers, and thus avoid using 
right heart catheterizations as frequently. 
Limitations 
Fo the studies of skin biomarkers, we cannot be certain that biomarkers correlated 
with skin disease do not also reflect burden of disease elsewhere. These patients varied in 
other clinical manifestations and measures, which might have influenced levels of the 
serum proteins independent of the degree of skin disease. Such clinical measures include; 
serial change in forced vital capacity, measures of vascular severity (such as digital 
ulcers, pulmonary arterial hypertension).   
Another limitation is that design of the mRNA studies genes were first selected 
based on their correlations with MRSS, and there was no assessment to whether they also 
differed healthy controls. It seems reasonable that those proteins that would be intricately 
involved in the pathogenesis of the disease would not only correlate with MRSS but also 
be differentially regulated from healthy controls. A limitation, specific to the proteins 
chosen from the high throughput analysis to be focused on, was that they were parsed 
based on combined measures of differential regulation and correlation with MRSS. Using 
this method of selection could have intrinsically excluded some proteins that were highly 
correlative with MRSS and not differentially regulated, and vice versa. However the main 
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goal of the pharmacodynamic biomarker was accomplished, both mRNA and protein 
markers were described that could change in a trial.   
There are limitations to SSc-PAH biomarker as well. There were patients in the 
validation sets that were treated with various drugs including endothelial inhibitors and 
samples were not collected simultaneously to RHC. Additionally some of the patients had 
radiographic ILD as well as SSc-PAH. Further limitations include that there has been no 
testing of Midkine or FSTL3 on other subset of SSc patients that might also show 
increased protein concentrations of those specific proteins including patients with heart 
failure or kidney disease. Also other diseases have not been tested for elevated levels of 
Midkine and FSTL3 such as idiopathic pulmonary fibrosis, or pulmonary hypertension.  
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Appendixes 
COPYRIGHT PERMISSIONS  
CHAPTER TWO:  
DECREASED BIOMARKERS AND CLINICAL IMPROVEMENT IN SYSTEMIC 
SCLEROSIS AFTER FRESOLIMUMAB 
Data and text used in this chapter were originally published as: Rice LM, Padilla 
CM, McLaughlin SR, Mathes A, Ziemek J, Goummih S, Nakerakanti S, York M, Fatina 
G, Whitfield ML, Spiera RF, Christmann RB, Gordon JK, Weinberg J, Simms RW, 
Lafyatis R (2015) Fresolimumab treatment decreases biomarkers and improves clinical 
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third parties (including such third parties' rights of copyright, privacy, publicity, or other
tangible or intangible property), or is otherwise illegal, sexually explicit or obscene. In
addition, User may not conjoin a Work with any other material that may result in damage to
the reputation of the Rightsholder. User agrees to inform CCC if it becomes aware of any
infringement of any rights in a Work and to cooperate with any reasonable request of CCC
or the Rightsholder in connection therewith.
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4. Indemnity. User hereby indemnifies and agrees to defend the Rightsholder and CCC, and
their respective employees and directors, against all claims, liability, damages, costs and
expenses, including legal fees and expenses, arising out of any use of a Work beyond the
scope of the rights granted herein, or any use of a Work which has been altered in any
unauthorized way by User, including claims of defamation or infringement of rights of
copyright, publicity, privacy or other tangible or intangible property.
5. Limitation of Liability. UNDER NO CIRCUMSTANCES WILL CCC OR THE
RIGHTSHOLDER BE LIABLE FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL OR
INCIDENTAL DAMAGES (INCLUDING WITHOUT LIMITATION DAMAGES FOR
LOSS OF BUSINESS PROFITS OR INFORMATION, OR FOR BUSINESS
INTERRUPTION) ARISING OUT OF THE USE OR INABILITY TO USE A WORK,
EVEN IF ONE OF THEM HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES. In any event, the total liability of the Rightsholder and CCC (including their
respective employees and directors) shall not exceed the total amount actually paid by User
for this license. User assumes full liability for the actions and omissions of its principals,
employees, agents, affiliates, successors and assigns.
6. Limited Warranties. THE WORK(S) AND RIGHT(S) ARE PROVIDED “AS IS”. CCC
HAS THE RIGHT TO GRANT TO USER THE RIGHTS GRANTED IN THE ORDER
CONFIRMATION DOCUMENT. CCC AND THE RIGHTSHOLDER DISCLAIM ALL
OTHER WARRANTIES RELATING TO THE WORK(S) AND RIGHT(S), EITHER
EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION IMPLIED
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE. ADDITIONAL RIGHTS MAY BE REQUIRED TO USE ILLUSTRATIONS,
GRAPHS, PHOTOGRAPHS, ABSTRACTS, INSERTS OR OTHER PORTIONS OF THE
WORK (AS OPPOSED TO THE ENTIRE WORK) IN A MANNER CONTEMPLATED
BY USER; USER UNDERSTANDS AND AGREES THAT NEITHER CCC NOR THE
RIGHTSHOLDER MAY HAVE SUCH ADDITIONAL RIGHTS TO GRANT.
7. Effect of Breach. Any failure by User to pay any amount when due, or any use by User of
a Work beyond the scope of the license set forth in the Order Confirmation and/or these
terms and conditions, shall be a material breach of the license created by the Order
Confirmation and these terms and conditions. Any breach not cured within 30 days of
written notice thereof shall result in immediate termination of such license without further
notice. Any unauthorized (but licensable) use of a Work that is terminated immediately upon
notice thereof may be liquidated by payment of the Rightsholder's ordinary license price
therefor; any unauthorized (and unlicensable) use that is not terminated immediately for any
reason (including, for example, because materials containing the Work cannot reasonably be
recalled) will be subject to all remedies available at law or in equity, but in no event to a
payment of less than three times the Rightsholder's ordinary license price for the most
closely analogous licensable use plus Rightsholder's and/or CCC's costs and expenses
incurred in collecting such payment.
8. Miscellaneous.
8.1 User acknowledges that CCC may, from time to time, make changes or additions to the
Service or to these terms and conditions, and CCC reserves the right to send notice to the
User by electronic mail or otherwise for the purposes of notifying User of such changes or
additions; provided that any such changes or additions shall not apply to permissions already
secured and paid for.
8.2 Use of User-related information collected through the Service is governed by CCC’s
privacy policy, available online here:
http://www.copyright.com/content/cc3/en/tools/footer/privacypolicy.html.
8.3 The licensing transaction described in the Order Confirmation is personal to User.
Therefore, User may not assign or transfer to any other person (whether a natural person or
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an organization of any kind) the license created by the Order Confirmation and these terms
and conditions or any rights granted hereunder; provided, however, that User may assign
such license in its entirety on written notice to CCC in the event of a transfer of all or
substantially all of User’s rights in the new material which includes the Work(s) licensed
under this Service.
8.4 No amendment or waiver of any terms is binding unless set forth in writing and signed
by the parties. The Rightsholder and CCC hereby object to any terms contained in any
writing prepared by the User or its principals, employees, agents or affiliates and purporting
to govern or otherwise relate to the licensing transaction described in the Order
Confirmation, which terms are in any way inconsistent with any terms set forth in the Order
Confirmation and/or in these terms and conditions or CCC's standard operating procedures,
whether such writing is prepared prior to, simultaneously with or subsequent to the Order
Confirmation, and whether such writing appears on a copy of the Order Confirmation or in a
separate instrument.
8.5 The licensing transaction described in the Order Confirmation document shall be
governed by and construed under the law of the State of New York, USA, without regard to
the principles thereof of conflicts of law. Any case, controversy, suit, action, or proceeding
arising out of, in connection with, or related to such licensing transaction shall be brought, at
CCC's sole discretion, in any federal or state court located in the County of New York, State
of New York, USA, or in any federal or state court whose geographical jurisdiction covers
the location of the Rightsholder set forth in the Order Confirmation. The parties expressly
submit to the personal jurisdiction and venue of each such federal or state court.If you have
any comments or questions about the Service or Copyright Clearance Center, please contact
us at 978-750-8400 or send an e-mail to info@copyright.com.
v 1.1
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.
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CHAPTER THREE:  
A LONGITUDINAL BIOMARKER FOR THE EXTENT OF SKIN DISEASE IN 
PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS 
Data and text used in this chapter were originally published as: Rice LM, Ziemek 
J, Stratton EA, McLaughlin SR, Padilla CM, Mathes AL, Christmann RB, Stifano G, 
Browning JL, Whitfield ML, Spiera RF, Gordon JK, Simms RW, Zhang Y, Lafyatis R 
(2015) A Longitudinal Biomarker for the Extent of Skin Disease in Patients with Diffuse 
Cutaneous Systemic Sclerosis. Arthritis & rheumatology. 
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This copyrighted material is owned by or exclusively licensed to John Wiley & Sons, Inc. or
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which a Wiley Company has exclusive publishing rights in relation to a particular work
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(along with the billing and payment terms and conditions established by the Copyright
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Terms and Conditions
The materials you have requested permission to reproduce or reuse (the "Wiley
Materials") are protected by copyright. 
You are hereby granted a personal, non-exclusive, non-sub licensable (on a stand-
alone basis), non-transferable, worldwide, limited license to reproduce the Wiley
Materials for the purpose specified in the licensing process. This license, and any
CONTENT (PDF or image file) purchased as part of your order, is for a one-time
use only and limited to any maximum distribution number specified in the license. The
first instance of republication or reuse granted by this license must be completed
within two years of the date of the grant of this license (although copies prepared
before the end date may be distributed thereafter). The Wiley Materials shall not be
used in any other manner or for any other purpose, beyond what is granted in the
license. Permission is granted subject to an appropriate acknowledgement given to the
author, title of the material/book/journal and the publisher. You shall also duplicate the
copyright notice that appears in the Wiley publication in your use of the Wiley
Material. Permission is also granted on the understanding that nowhere in the text is a
previously published source acknowledged for all or part of this Wiley Material. Any
third party content is expressly excluded from this permission.
With respect to the Wiley Materials, all rights are reserved. Except as expressly
granted by the terms of the license, no part of the Wiley Materials may be copied,
modified, adapted (except for minor reformatting required by the new Publication),
translated, reproduced, transferred or distributed, in any form or by any means, and no
derivative works may be made based on the Wiley Materials without the prior
permission of the respective copyright owner.For STM Signatory Publishers
clearing permission under the terms of the STM Permissions Guidelines only, the
terms of the license are extended to include subsequent editions and for editions
in other languages, provided such editions are for the work as a whole in situ and
does not involve the separate exploitation of the permitted figures or extracts,
You may not alter, remove or suppress in any manner any copyright, trademark or
other notices displayed by the Wiley Materials. You may not license, rent, sell, loan,
lease, pledge, offer as security, transfer or assign the Wiley Materials on a stand-alone
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basis, or any of the rights granted to you hereunder to any other person.
The Wiley Materials and all of the intellectual property rights therein shall at all times
remain the exclusive property of John Wiley & Sons Inc, the Wiley Companies, or
their respective licensors, and your interest therein is only that of having possession of
and the right to reproduce the Wiley Materials pursuant to Section 2 herein during the
continuance of this Agreement. You agree that you own no right, title or interest in or
to the Wiley Materials or any of the intellectual property rights therein. You shall have
no rights hereunder other than the license as provided for above in Section 2. No right,
license or interest to any trademark, trade name, service mark or other branding
("Marks") of WILEY or its licensors is granted hereunder, and you agree that you
shall not assert any such right, license or interest with respect thereto
NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR
REPRESENTATION OF ANY KIND TO YOU OR ANY THIRD PARTY,
EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE MATERIALS
OR THE ACCURACY OF ANY INFORMATION CONTAINED IN THE
MATERIALS, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED
WARRANTY OF MERCHANTABILITY, ACCURACY, SATISFACTORY
QUALITY, FITNESS FOR A PARTICULAR PURPOSE, USABILITY,
INTEGRATION OR NON-INFRINGEMENT AND ALL SUCH WARRANTIES
ARE HEREBY EXCLUDED BY WILEY AND ITS LICENSORS AND WAIVED
BY YOU. 
WILEY shall have the right to terminate this Agreement immediately upon breach of
this Agreement by you.
You shall indemnify, defend and hold harmless WILEY, its Licensors and their
respective directors, officers, agents and employees, from and against any actual or
threatened claims, demands, causes of action or proceedings arising from any breach
of this Agreement by you.
IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR
ANY OTHER PARTY OR ANY OTHER PERSON OR ENTITY FOR ANY
SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY OR
PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN
CONNECTION WITH THE DOWNLOADING, PROVISIONING, VIEWING OR
USE OF THE MATERIALS REGARDLESS OF THE FORM OF ACTION,
WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, TORT,
NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, WITHOUT
LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, FILES, USE,
BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES), AND WHETHER
OR NOT THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES. THIS LIMITATION SHALL APPLY NOTWITHSTANDING ANY
FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED
HEREIN. 
Should any provision of this Agreement be held by a court of competent jurisdiction
to be illegal, invalid, or unenforceable, that provision shall be deemed amended to
achieve as nearly as possible the same economic effect as the original provision, and
the legality, validity and enforceability of the remaining provisions of this Agreement
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shall not be affected or impaired thereby. 
The failure of either party to enforce any term or condition of this Agreement shall not
constitute a waiver of either party's right to enforce each and every term and condition
of this Agreement. No breach under this agreement shall be deemed waived or
excused by either party unless such waiver or consent is in writing signed by the party
granting such waiver or consent. The waiver by or consent of a party to a breach of
any provision of this Agreement shall not operate or be construed as a waiver of or
consent to any other or subsequent breach by such other party. 
This Agreement may not be assigned (including by operation of law or otherwise) by
you without WILEY's prior written consent.
Any fee required for this permission shall be non-refundable after thirty (30) days
from receipt by the CCC.
These terms and conditions together with CCC's Billing and Payment terms and
conditions (which are incorporated herein) form the entire agreement between you and
WILEY concerning this licensing transaction and (in the absence of fraud) supersedes
all prior agreements and representations of the parties, oral or written. This Agreement
may not be amended except in writing signed by both parties. This Agreement shall be
binding upon and inure to the benefit of the parties' successors, legal representatives,
and authorized assigns. 
In the event of any conflict between your obligations established by these terms and
conditions and those established by CCC's Billing and Payment terms and conditions,
these terms and conditions shall prevail.
WILEY expressly reserves all rights not specifically granted in the combination of (i)
the license details provided by you and accepted in the course of this licensing
transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms
and conditions.
This Agreement will be void if the Type of Use, Format, Circulation, or Requestor
Type was misrepresented during the licensing process.
This Agreement shall be governed by and construed in accordance with the laws of
the State of New York, USA, without regards to such state's conflict of law rules. Any
legal action, suit or proceeding arising out of or relating to these Terms and Conditions
or the breach thereof shall be instituted in a court of competent jurisdiction in New
York County in the State of New York in the United States of America and each party
hereby consents and submits to the personal jurisdiction of such court, waives any
objection to venue in such court and consents to service of process by registered or
certified mail, return receipt requested, at the last known address of such party.
WILEY OPEN ACCESS TERMS AND CONDITIONS
Wiley Publishes Open Access Articles in fully Open Access Journals and in Subscription
journals offering Online Open. Although most of the fully Open Access journals publish
open access articles under the terms of the Creative Commons Attribution (CC BY) License
only, the subscription journals and a few of the Open Access Journals offer a choice of
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Creative Commons Licenses. The license type is clearly identified on the article.
The Creative Commons Attribution License
The Creative Commons Attribution License (CC-BY) allows users to copy, distribute and
transmit an article, adapt the article and make commercial use of the article. The CC-BY
license permits commercial and non-
Creative Commons Attribution Non-Commercial License
The Creative Commons Attribution Non-Commercial (CC-BY-NC)License permits use,
distribution and reproduction in any medium, provided the original work is properly cited
and is not used for commercial purposes.(see below)
Creative Commons Attribution-Non-Commercial-NoDerivs License
The Creative Commons Attribution Non-Commercial-NoDerivs License (CC-BY-NC-ND)
permits use, distribution and reproduction in any medium, provided the original work is
properly cited, is not used for commercial purposes and no modifications or adaptations are
made. (see below)
Use by commercial "for-profit" organizations
Use of Wiley Open Access articles for commercial, promotional, or marketing purposes
requires further explicit permission from Wiley and will be subject to a fee.
Further details can be found on Wiley Online Library
http://olabout.wiley.com/WileyCDA/Section/id-410895.html
Other Terms and Conditions:
v1.10 Last updated September 2015
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.
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CHAPTER FOUR:  
LOCAL SKIN GENE EXPRESSION REFLECTS BOTH LOCAL AND SYSTEMIC 
SKIN DISEASE IN PATIENTS WITH SYSTMEIC SCLEROSIS 
Data and text used in this chapter were originally published as: Rice LM, Stifano 
G, Ziemek J, Lafyatis R (2015) Local skin gene expression reflects both local and 
systemic skin disease in patients with systemic sclerosis. Rheumatology. 
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reproduced, drawn or modified from an earlier source it will be necessary for you to clear this permission with the original
publisher as well. If this permission has not been obtained, please note that this material cannot be included in your
publication/photocopies.
8. While you may exercise the rights licensed immediately upon issuance of the license at the end of the licensing process
for the transaction, provided that you have disclosed complete and accurate details of your proposed use, no license is
finally effective unless and until full payment is received from you (either by Oxford University Press or by Copyright
Clearance Center (CCC)) as provided in CCC's Billing and Payment terms and conditions. If full payment is not received on
a timely basis, then any license preliminarily granted shall be deemed automatically revoked and shall be void as if never
granted. Further, in the event that you breach any of these terms and conditions or any of CCC's Billing and Payment terms
and conditions, the license is automatically revoked and shall be void as if never granted. Use of materials as described in a
revoked license, as well as any use of the materials beyond the scope of an unrevoked license, may constitute copyright
infringement and Oxford University Press reserves the right to take any and all action to protect its copyright in the materials.
9. This license is personal to you and may not be sublicensed, assigned or transferred by you to any other person without
Oxford University Press’s written permission.
10. Oxford University Press reserves all rights not specifically granted in the combination of (i) the license details provided by
you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) CCC’s Billing and
Payment terms and conditions.
11. You hereby indemnify and agree to hold harmless Oxford University Press and CCC, and their respective officers,
directors, employs and agents, from and against any and all claims arising out of your use of the licensed material other than
as specifically authorized pursuant to this license.
12. Other Terms and Conditions:
v1.4
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1-978-646-2777.
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